ID   NF1_HUMAN               Reviewed;        2839 AA.
AC   P21359; O00662; Q14284; Q14930; Q14931; Q9UMK3;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   13-NOV-2019, entry version 231.
DE   RecName: Full=Neurofibromin;
DE   AltName: Full=Neurofibromatosis-related protein NF-1;
DE   Contains:
DE     RecName: Full=Neurofibromin truncated;
GN   Name=NF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=1457041; DOI=10.1089/dna.1992.11.727;
RA   Bernards A., Haase V.H., Murthy A.E., Menon A., Hannigan G.E.,
RA   Gusella J.F.;
RT   "Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and
RT   absence of expression in a neuroblastoma line.";
RL   DNA Cell Biol. 11:727-734(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2134734; DOI=10.1126/science.2134734;
RA   Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M.,
RA   Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L.,
RA   Brownstein B.H., Collins F.S.;
RT   "Type 1 neurofibromatosis gene: identification of a large transcript
RT   disrupted in three NF1 patients.";
RL   Science 249:181-186(1990).
RN   [3]
RP   ERRATUM.
RX   PubMed=2125369;
RA   Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M.,
RA   Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L.,
RA   Brownstein B.H., Collins F.S.;
RL   Science 250:1749-1749(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1783401; DOI=10.1016/0888-7543(91)90017-9;
RA   Marchuk D.A., Saulino A.M., Tavakkol R., Swaroop M., Wallace M.R.,
RA   Andersen L.B., Mitchell A.L., Gutmann D.H., Boguski M.S.,
RA   Collins F.S.;
RT   "cDNA cloning of the type 1 neurofibromatosis gene: complete sequence
RT   of the NF1 gene product.";
RL   Genomics 11:931-940(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RC   TISSUE=Placenta;
RX   PubMed=1339276; DOI=10.1016/0006-291x(92)91294-z;
RA   Suzuki H., Takahashi K., Kubota Y., Shibahara S.;
RT   "Molecular cloning of a cDNA coding for neurofibromatosis type 1
RT   protein isoform lacking the domain related to ras GTPase-activating
RT   protein.";
RL   Biochem. Biophys. Res. Commun. 187:984-990(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Kidney;
RX   PubMed=7570581; DOI=10.1620/tjem.175.225;
RA   Suzuki H., Takahashi K., Shibahara S.;
RT   "Evidence for the presence of two amino-terminal isoforms of
RT   neurofibromin, a gene product responsible for neurofibromatosis type
RT   1.";
RL   Tohoku J. Exp. Med. 175:225-233(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-80; LEU-678;
RP   HIS-1422 AND LEU-2511.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 335-2839 (ISOFORM 1), AND
RP   VARIANT NF1 PRO-1953.
RX   PubMed=2114220; DOI=10.1016/0092-8674(90)90253-b;
RA   Cawthon R.M., Weiss R., Xu G., Viskochil D., Culver M., Stevens J.,
RA   Robertson M., Dunn D., Gesteland R., O'Connell P., White R.;
RT   "A major segment of the neurofibromatosis type 1 gene: cDNA sequence,
RT   genomic structure, and point mutations.";
RL   Cell 62:193-201(1990).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 335-2839 (ISOFORMS 1 AND 6).
RX   PubMed=2116237; DOI=10.1016/0092-8674(90)90024-9;
RA   Xu G., O'Connell P., Viskochil D., Cawthon R.M., Robertson M.,
RA   Culver M., Dunn D., Stevens J., Gesteland R., White R., Weiss R.;
RT   "The neurofibromatosis type 1 gene encodes a protein related to GAP.";
RL   Cell 62:599-608(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 707-782.
RX   PubMed=9002664; DOI=10.1093/hmg/6.1.9;
RA   Regnier V., Meddeb M., Lecointre G., Richard F., Duverger A.,
RA   Nguyen V.C., Dutrillaux B., Bernheim A., Danglot G.;
RT   "Emergence and scattering of multiple neurofibromatosis (NF1)-related
RT   sequences during hominoid evolution suggest a process of
RT   pericentromeric interchromosomal transposition.";
RL   Hum. Mol. Genet. 6:9-16(1997).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 751-1611 (ISOFORMS 1 AND 2).
RX   PubMed=7774960; DOI=10.1016/0888-7543(95)80104-t;
RA   Li Y., O'Connell P., Breidenbach H.H., Cawthon R.M., Stevens J.,
RA   Xu G., Neil S., Robertson M., White R., Viskochil D.;
RT   "Genomic organization of the neurofibromatosis 1 gene (NF1).";
RL   Genomics 25:9-18(1995).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1090-1598 (ISOFORM 4).
RX   PubMed=2121370; DOI=10.1016/0092-8674(90)90150-d;
RA   Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J.,
RA   Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M.,
RA   Innis M., McCormick F.;
RT   "The GAP-related domain of the neurofibromatosis type 1 gene product
RT   interacts with ras p21.";
RL   Cell 63:843-849(1990).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1168-1566 (ISOFORMS 1 AND 2).
RX   PubMed=1923522;
RA   Nishi T., Lee P.S., Oka K., Levin V.A., Tanase S., Morino Y., Saya H.;
RT   "Differential expression of two types of the neurofibromatosis type 1
RT   (NF1) gene transcripts related to neuronal differentiation.";
RL   Oncogene 6:1555-1559(1991).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM 2), FUNCTION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=8417346; DOI=10.1128/mcb.13.1.487;
RA   Andersen L.B., Ballester R., Marchuk D.A., Chang E., Gutmann D.H.,
RA   Saulino A.M., Camonis J., Wigler M., Collins F.S.;
RT   "A conserved alternative splice in the von Recklinghausen
RT   neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both
RT   of which have GTPase-activating protein activity.";
RL   Mol. Cell. Biol. 13:487-495(1993).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM 2).
RX   PubMed=1662505; DOI=10.1016/0006-291x(91)92029-j;
RA   Suzuki Y., Suzuki H., Kayama T., Yoshimoto T., Shibahara S.;
RT   "Brain tumors predominantly express the neurofibromatosis type 1 gene
RT   transcripts containing the 63 base insert in the region coding for
RT   GTPase activating protein-related domain.";
RL   Biochem. Biophys. Res. Commun. 181:955-961(1991).
RN   [18]
RP   FUNCTION.
RX   PubMed=2121371; DOI=10.1016/0092-8674(90)90151-4;
RA   Ballester R., Marchuk D.A., Boguski M.S., Saulino A.M., Letcher R.,
RA   Wigler M., Collins F.S.;
RT   "The NF1 locus encodes a protein functionally related to mammalian GAP
RT   and yeast IRA proteins.";
RL   Cell 63:851-859(1990).
RN   [19]
RP   RNA EDITING.
RX   PubMed=8602361; DOI=10.1093/nar/24.3.478;
RA   Skuse G.R., Cappione A.J., Sowden M., Metheny L.J., Smith H.C.;
RT   "The neurofibromatosis type I messenger RNA undergoes base-
RT   modification RNA editing.";
RL   Nucleic Acids Res. 24:478-485(1996).
RN   [20]
RP   RNA EDITING.
RX   PubMed=11727199; DOI=10.1086/337952;
RA   Mukhopadhyay D., Anant S., Lee R.M., Kennedy S., Viskochil D.,
RA   Davidson N.O.;
RT   "C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that
RT   express both the type II transcript and apobec-1, the catalytic
RT   subunit of the apolipoprotein B mRNA-editing enzyme.";
RL   Am. J. Hum. Genet. 70:38-50(2002).
RN   [21]
RP   REVIEW ON VARIANTS.
RX   PubMed=7981724; DOI=10.1002/humu.1380040202;
RA   Upadhyaya M., Shaw D.J., Harper P.S.;
RT   "Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis
RT   and polymorphisms in the NF1 gene.";
RL   Hum. Mutat. 4:83-101(1994).
RN   [22]
RP   REVIEW ON VARIANTS.
RX   PubMed=8825042; DOI=10.1136/jmg.33.1.2;
RA   Shen M.H., Harper P.S., Upadhyaya M.;
RT   "Molecular genetics of neurofibromatosis type 1 (NF1).";
RL   J. Med. Genet. 33:2-17(1996).
RN   [23]
RP   SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=14988005; DOI=10.1016/s0014-5793(04)00078-x;
RA   Vandenbroucke I., Van Oostveldt P., Coene E., De Paepe A.,
RA   Messiaen L.;
RT   "Neurofibromin is actively transported to the nucleus.";
RL   FEBS Lett. 560:98-102(2004).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-2188; SER-2515;
RP   SER-2521 AND SER-2543, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876 AND
RP   SER-2515, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864 AND SER-2817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   INTERACTION WITH HTR6.
RX   PubMed=23027611; DOI=10.1002/emmm.201201410;
RA   Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F.,
RA   Watson D.J., Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P.,
RA   Herve D., Fone K.C., Bockaert J., Millan M.J., Marin P.;
RT   "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed
RT   cognition in schizophrenia.";
RL   EMBO Mol. Med. 4:1043-1056(2012).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876; SER-2188;
RP   SER-2515; SER-2521; SER-2523; SER-2543; THR-2565; SER-2597 AND
RP   SER-2802, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1198-1551.
RX   PubMed=9687500; DOI=10.1093/emboj/17.15.4313;
RA   Scheffzek K., Ahmadian M.R., Wiesmuller L., Kabsch W., Stege P.,
RA   Schmitz F., Wittinghofer A.;
RT   "Structural analysis of the GAP-related domain from neurofibromin and
RT   its implications.";
RL   EMBO J. 17:4313-4327(1998).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1581-1837, LIPID-BINDING,
RP   DOMAIN, AND MUTAGENESIS OF LYS-1691; ARG-1695; ARG-1769 AND LYS-1771.
RX   PubMed=16397625; DOI=10.1038/sj.embor.7400602;
RA   D'Angelo I., Welti S., Bonneau F., Scheffzek K.;
RT   "A novel bipartite phospholipid-binding module in the
RT   neurofibromatosis type 1 protein.";
RL   EMBO Rep. 7:174-179(2006).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1566-1837 IN COMPLEX WITH
RP   PHOSPHOLIPID, LIPID-BINDING, AND DOMAIN.
RX   PubMed=17187824; DOI=10.1016/j.jmb.2006.11.055;
RA   Welti S., Fraterman S., D'Angelo I., Wilm M., Scheffzek K.;
RT   "The sec14 homology module of neurofibromin binds cellular
RT   glycerophospholipids: mass spectrometry and structure of a lipid
RT   complex.";
RL   J. Mol. Biol. 366:551-562(2007).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 1581-1837 OF VARIANT NF1
RP   VAL-1605 AND MUTANT LYS-1771 DEL IN COMPLEX WITH LIPID,
RP   CHARACTERIZATION OF VARIANT NF1 VAL-1605, MUTAGENESIS OF LYS-1771,
RP   LIPID-BINDING, AND DOMAIN.
RX   PubMed=21089070; DOI=10.1002/humu.21405;
RA   Welti S., Kuhn S., D'Angelo I., Brugger B., Kaufmann D., Scheffzek K.;
RT   "Structural and biochemical consequences of NF1 associated
RT   nontruncating mutations in the Sec14-PH module of neurofibromin.";
RL   Hum. Mutat. 32:191-197(2011).
RN   [40]
RP   VARIANT GLU-1444.
RX   PubMed=1568247; DOI=10.1016/0092-8674(92)90408-5;
RA   Li Y., Bollag G., Clark R., Stevens J., Conroy L., Fults D., Ward K.,
RA   Friedman E., Samowitz W., Robertson M., Bradley P., McCormick F.,
RA   White R., Cawthon R.M.;
RT   "Somatic mutations in the neurofibromatosis 1 gene in human tumors.";
RL   Cell 69:275-281(1992).
RN   [41]
RP   VARIANTS NF1 MET-2164 AND ASN-2192.
RX   PubMed=1302608; DOI=10.1093/hmg/1.9.735;
RA   Upadhyaya M., Shen M.H., Cherryson A., Farnham J., Maynard J.,
RA   Huson S.M., Harper P.S.;
RT   "Analysis of mutations at the neurofibromatosis 1 (NF1) locus.";
RL   Hum. Mol. Genet. 1:735-740(1992).
RN   [42]
RP   VARIANT GLY-HIS-GLU-GLN-GLN-LYS-LEU-PRO-ALA-ALA-THR-LEU-ALA-LEU-1733
RP   INS.
RX   PubMed=8317503;
RA   Tassabehji M., Strachan T., Sharland M., Colley A., Donnai D.,
RA   Harris R., Thakker N.;
RT   "Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon
RT   in a family with features of Watson syndrome and Noonan syndrome.";
RL   Am. J. Hum. Genet. 53:90-95(1993).
RN   [43]
RP   VARIANT MET-991 DEL.
RX   PubMed=7904209; DOI=10.1093/hmg/2.11.1861;
RA   Shen M.H., Harper P.S., Upadhyaya M.;
RT   "Neurofibromatosis type 1 (NF1): the search for mutations by PCR-
RT   heteroduplex analysis on Hydrolink gels.";
RL   Hum. Mol. Genet. 2:1861-1864(1993).
RN   [44]
RP   VARIANTS NF1 ASP-1166 AND ARG-1440.
RX   PubMed=7981679; DOI=10.1093/hmg/3.7.1109;
RA   Purandare S.M., Lanyon W.G., Connor J.M.;
RT   "Characterisation of inherited and sporadic mutations in
RT   neurofibromatosis type-1.";
RL   Hum. Mol. Genet. 3:1109-1115(1994).
RN   [45]
RP   VARIANT NF1 2387-ASN-PHE-2388 DEL.
RX   PubMed=8081387; DOI=10.1002/humu.1380030404;
RA   Abernathy C.R., Colman S.D., Kousseff B.G., Wallace M.R.;
RT   "Two NF1 mutations: frameshift in the GAP-related domain, and loss of
RT   two codons toward the 3' end of the gene.";
RL   Hum. Mutat. 3:347-352(1994).
RN   [46]
RP   VARIANT NF1 ALA-2631.
RX   PubMed=8544190; DOI=10.1136/jmg.32.9.706;
RA   Upadhyaya M., Maynard J., Osborn M.J., Huson S.M., Ponder M.,
RA   Ponder B.A.J., Harper P.S.;
RT   "Characterisation of germline mutations in the neurofibromatosis type
RT   1 (NF1) gene.";
RL   J. Med. Genet. 32:706-710(1995).
RN   [47]
RP   VARIANT NF1 ARG-629.
RX   PubMed=8834249; DOI=10.1007/bf02267073;
RA   Gasparini P., D'Agruma L., de Cillis G.P., Balestrazzi P.,
RA   Mingarelli R., Zelante L.;
RT   "Scanning the first part of the neurofibromatosis type 1 gene by RNA-
RT   SSCP: identification of three novel mutations and of two new
RT   polymorphisms.";
RL   Hum. Genet. 97:492-495(1996).
RN   [48]
RP   VARIANT NF1 ARG-1035.
RX   PubMed=8807336;
RX   DOI=10.1002/(sici)1098-1004(1996)8:1<51::aid-humu7>3.0.co;2-s;
RA   Wu R., Legius E., Robberecht W., Dumoulin M., Cassiman J.-J.,
RA   Fryns J.-P.;
RT   "Neurofibromatosis type I gene mutation in a patient with features of
RT   LEOPARD syndrome.";
RL   Hum. Mutat. 8:51-56(1996).
RN   [49]
RP   VARIANTS NF1 SER-1412; GLN-1440; GLU-1444 AND GLY-1489.
RX   PubMed=9003501; DOI=10.1007/s004390050317;
RA   Upadhyaya M., Osborn M.J., Maynard J., Kim M.R., Tamanoi F.,
RA   Cooper D.N.;
RT   "Mutational and functional analysis of the neurofibromatosis type 1
RT   (NF1) gene.";
RL   Hum. Genet. 99:88-92(1997).
RN   [50]
RP   VARIANTS NF1 ARG-844 AND PRO-898.
RX   PubMed=9150739; DOI=10.1007/s004390050427;
RA   Maynard J., Krawczak M., Upadhyaya M.;
RT   "Characterization and significance of nine novel mutations in exon 16
RT   of the neurofibromatosis type 1 (NF1) gene.";
RL   Hum. Genet. 99:674-676(1997).
RN   [51]
RP   VARIANT NF1 ARG-1952.
RX   PubMed=9101300;
RX   DOI=10.1002/(sici)1098-1004(1997)9:4<366::aid-humu12>3.0.co;2-0;
RA   Hudson J., Wu C.L., Tassabehji M., Summers E.M., Simon S., Super M.,
RA   Donnai D., Thakker N.;
RT   "Novel and recurrent mutations in the neurofibromatosis type 1 (NF1)
RT   gene.";
RL   Hum. Mutat. 9:366-367(1997).
RN   [52]
RP   VARIANTS NF1 GLY-338 AND TRP-1611.
RX   PubMed=9298829;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:3<248::AID-HUMU14>3.3.CO;2-D;
RA   Upadhyaya M., Maynard J., Osborn M.J., Harper P.S.;
RT   "Six novel mutations in the neurofibromatosis type 1 (NF1) gene.";
RL   Hum. Mutat. 10:248-250(1997).
RN   [53]
RP   VARIANT NF1 PRO-1276.
RX   PubMed=9668168; DOI=10.1093/hmg/7.8.1261;
RA   Klose A., Ahmadian M.R., Schuelke M., Scheffzek K., Hoffmeyer S.,
RA   Gewies A., Schmitz F., Kaufmann D., Peters H., Wittinghofer A.,
RA   Nuernberg P.;
RT   "Selective disactivation of neurofibromin GAP activity in
RT   neurofibromatosis type 1 (NF1).";
RL   Hum. Mol. Genet. 7:1261-1268(1998).
RN   [54]
RP   VARIANTS NF1 HIS-765 AND GLY-1204.
RX   PubMed=10336779;
RX   DOI=10.1002/(sici)1098-1004(1998)11:5<411::aid-humu11>3.0.co;2-2;
RA   Krkljus S., Abernathy C.R., Johnson J.S., Williams C.A.,
RA   Driscoll D.J., Zori R., Stalker H.J., Rasmussen S.A., Collins F.S.,
RA   Kousseff B.G., Baumbach L., Wallace M.R.;
RT   "Analysis of CpG C-to-T mutations in neurofibromatosis type 1.";
RL   Hum. Mutat. 11:411-411(1998).
RN   [55]
RP   VARIANT NF1 PRO-508.
RX   PubMed=11258625; DOI=10.1097/00125817-199909000-00002;
RA   Messiaen L.M., Callens T., Roux K.J., Mortier G.R., De Paepe A.,
RA   Abramowicz M., Pericak-Vance M.A., Vance J.M., Wallace M.R.;
RT   "Exon 10b of the NF1 gene represents a mutational hotspot and harbors
RT   a recurrent missense mutation Y489C associated with aberrant
RT   splicing.";
RL   Genet. Med. 1:248-253(1999).
RN   [56]
RP   VARIANT NF1 PRO-1446.
RX   PubMed=10220149;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<337::AID-HUMU12>3.0.CO;2-F;
RA   Peters H., Hess D., Fahsold R., Schuelke M.;
RT   "A novel mutation L1425P in the GAP-region of the NF1 gene detected by
RT   temperature gradient gel electrophoresis (TGGE).";
RL   Hum. Mutat. 13:337-337(1999).
RN   [57]
RP   VARIANTS NF1 PRO-216; PRO-357; CYS-491; PRO-549; THR-581; ARG-583;
RP   PHE-665; PRO-695; PRO-763; SER-777; LYS-780; PRO-781; PRO-847;
RP   SER-1156; PRO-1250; GLN-1276; PRO-1276; PRO-1446; VAL-1605 AND
RP   ILE-2507, AND VARIANT GLU-176.
RX   PubMed=10712197; DOI=10.1086/302809;
RA   Fahsold R., Hoffmeyer S., Mischung C., Gille C., Ehlers C.,
RA   Kuecuekceylan N., Abdel-Nour M., Gewies A., Peters H., Kaufmann D.,
RA   Buske A., Tinschert S., Nuernberg P.;
RT   "Minor lesion mutational spectrum of the entire NF1 gene does not
RT   explain its high mutability but points to a functional domain upstream
RT   of the GAP-related domain.";
RL   Am. J. Hum. Genet. 66:790-818(2000).
RN   [58]
RP   VARIANTS NF1 SER-117; TRP-1204; PRO-1446 AND 2387-ASN-PHE-2388 DEL.
RX   PubMed=10607834; DOI=10.1093/hmg/9.2.237;
RA   Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C.,
RA   Estivill X.;
RT   "Mutations affecting mRNA splicing are the most common molecular
RT   defects in patients with neurofibromatosis type 1.";
RL   Hum. Mol. Genet. 9:237-247(2000).
RN   [59]
RP   ERRATUM.
RA   Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C.,
RA   Estivill X.;
RL   Hum. Mol. Genet. 9:659-659(2000).
RN   [60]
RP   VARIANT NF1 PHE-844.
RX   PubMed=10980545;
RX   DOI=10.1002/1098-1004(200009)16:3<274::AID-HUMU21>3.3.CO;2-6;
RA   Boulandet E.G., Pantel J., Cazeneuve C., Van Gijn M., Vidaud D.,
RA   Lemay S., Martin J., Zeller J., Revuz J., Goossens M., Amselem S.,
RA   Wolkenstein P.;
RT   "NF1 gene analysis focused on CpG-rich exons in a cohort of 93
RT   patients with neurofibromatosis type 1.";
RL   Hum. Mutat. 16:274-275(2000).
RN   [61]
RP   VARIANT SPINAL FSNF PRO-2088.
RX   PubMed=11704931; DOI=10.1086/324648;
RA   Kaufmann D., Mueller R., Bartelt B., Wolf M., Kunzi-Rapp K.,
RA   Hanemann C.O., Fahsold R., Hein C., Vogel W., Assum G.;
RT   "Spinal neurofibromatosis without cafe-au-lait macules in two families
RT   with null mutations of the NF1 gene.";
RL   Am. J. Hum. Genet. 69:1395-1400(2001).
RN   [62]
RP   VARIANTS NF1 LYS-780; CYS-784; PRO-1147; CYS-1193; ARG-1444; SER-1785;
RP   ASN-2012 AND LYS-2357.
RX   PubMed=11735023; DOI=10.1007/s004390100594;
RA   Han S.S., Cooper D.N., Upadhyaya M.N.;
RT   "Evaluation of denaturing high performance liquid chromatography
RT   (DHPLC) for the mutational analysis of the neurofibromatosis type 1 (
RT   NF1) gene.";
RL   Hum. Genet. 109:487-497(2001).
RN   [63]
RP   VARIANTS NF1 PHE-82; ARG-784 AND GLU-1444.
RX   PubMed=11857752; DOI=10.1002/humu.9018;
RA   Kluwe L., Friedrich R.E., Korf B., Fahsold R., Mautner V.-F.;
RT   "NF1 mutations in neurofibromatosis 1 patients with plexiform
RT   neurofibromas.";
RL   Hum. Mutat. 19:309-309(2002).
RN   [64]
RP   VARIANT NFNS GLU-1459 DEL.
RX   PubMed=12707950; DOI=10.1002/ajmg.a.20023;
RA   Baralle D., Mattocks C., Kalidas K., Elmslie F., Whittaker J.,
RA   Lees M., Ragge N., Patton M.A., Winter R.M., ffrench-Constant C.;
RT   "Different mutations in the NF1 gene are associated with
RT   neurofibromatosis-Noonan syndrome (NFNS).";
RL   Am. J. Med. Genet. A 119:1-8(2003).
RN   [65]
RP   VARIANTS NF1 TYR-93; VAL-604; ARG-844 AND PRO-898, AND VARIANTS
RP   ASP-74; GLU-176; ARG-712 AND GLN-1276.
RX   PubMed=12522551; DOI=10.1007/s00439-002-0858-4;
RA   Wang Q., Montmain G., Ruano E., Upadhyaya M., Dudley S., Liskay R.M.,
RA   Thibodeau S.N., Puisieux A.;
RT   "Neurofibromatosis type 1 gene as a mutational target in a mismatch
RT   repair-deficient cell type.";
RL   Hum. Genet. 112:117-123(2003).
RN   [66]
RP   VARIANTS NF1 LYS-780; PRO-847; GLU-848 AND ARG-968; ASN-1444; LEU-1953
RP   DEL AND ARG-2001.
RX   PubMed=12552569; DOI=10.1002/humu.9111;
RA   De Luca A., Buccino A., Gianni D., Mangino M., Giustini S.,
RA   Richetta A., Divona L., Calvieri S., Mingarelli R., Dallapiccola B.;
RT   "NF1 gene analysis based on DHPLC.";
RL   Hum. Mutat. 21:171-172(2003).
RN   [67]
RP   VARIANTS NF1 ARG-578; PRO-920 AND ALA-2221.
RX   PubMed=12746402; DOI=10.1136/jmg.40.5.368;
RA   Kluwe L., Tatagiba M., Fuensterer C., Mautner V.F.;
RT   "NF1 mutations and clinical spectrum in patients with spinal
RT   neurofibromas.";
RL   J. Med. Genet. 40:368-371(2003).
RN   [68]
RP   VARIANT NF1 VAL-186, AND CHARACTERIZATION OF VARIANT NF1 VAL-186.
RX   PubMed=15523642; DOI=10.1002/humu.20103;
RA   Zatkova A., Messiaen L., Vandenbroucke I., Wieser R., Fonatsch C.,
RA   Krainer A.R., Wimmer K.;
RT   "Disruption of exonic splicing enhancer elements is the principal
RT   cause of exon skipping associated with seven nonsense or missense
RT   alleles of NF1.";
RL   Hum. Mutat. 24:491-501(2004).
RN   [69]
RP   VARIANTS NF1 ASN-157; ARG-629; SER-777; LYS-780; ARG-784; PRO-847;
RP   GLU-848; ARG-968; ASN-1444; LEU-1953 DEL AND ARG-2001, AND VARIANT
RP   GLU-176.
RX   PubMed=15146469; DOI=10.1002/humu.9245;
RA   De Luca A., Schirinzi A., Buccino A., Bottillo I., Sinibaldi L.,
RA   Torrente I., Ciavarella A., Dottorini T., Porciello R., Giustini S.,
RA   Calvieri S., Dallapiccola B.;
RT   "Novel and recurrent mutations in the NF1 gene in Italian patients
RT   with neurofibromatosis type 1.";
RL   Hum. Mutat. 23:629-629(2004).
RN   [70]
RP   VARIANTS NF1 ARG-31; PRO-145; ARG-324; VAL-337; CYS-489; PRO-532;
RP   ARG-574; ARG-629; PHE-665; PHE-844; PRO-844; MET-991 DEL; VAL-1073;
RP   ARG-1196; GLY-1276; GLN-1276; GLU-1430; GLU-1459 DEL AND GLY-1489, AND
RP   VARIANTS GLU-176 AND CYS-873.
RX   PubMed=15060124; DOI=10.1136/jmg.2003.011890;
RA   Mattocks C., Baralle D., Tarpey P., ffrench-Constant C., Bobrow M.,
RA   Whittaker J.;
RT   "Automated comparative sequence analysis identifies mutations in 89%
RT   of NF1 patients and confirms a mutation cluster in exons 11-17
RT   distinct from the GAP related domain.";
RL   J. Med. Genet. 41:E48-E48(2004).
RN   [71]
RP   VARIANT NF1 PRO-1243.
RX   PubMed=15520408; DOI=10.1136/jmg.2004.021683;
RA   Ferner R.E., Hughes R.A.C., Hall S.M., Upadhyaya M., Johnson M.R.;
RT   "Neurofibromatous neuropathy in neurofibromatosis 1 (NF1).";
RL   J. Med. Genet. 41:837-841(2004).
RN   [72]
RP   VARIANT NF1 ARG-844.
RX   PubMed=15948193; DOI=10.1002/ajmg.a.30813;
RA   Bertola D.R., Pereira A.C., Passetti F., de Oliveira P.S.L.,
RA   Messiaen L., Gelb B.D., Kim C.A., Krieger J.E.;
RT   "Neurofibromatosis-Noonan syndrome: molecular evidence of the
RT   concurrence of both disorders in a patient.";
RL   Am. J. Med. Genet. A 136:242-245(2005).
RN   [73]
RP   VARIANTS NFNS ARG-194; GLU-1444; THR-1451; LEU-1453 AND GLU-1459 DEL.
RX   PubMed=16380919; DOI=10.1086/498454;
RA   De Luca A., Bottillo I., Sarkozy A., Carta C., Neri C., Bellacchio E.,
RA   Schirinzi A., Conti E., Zampino G., Battaglia A., Majore S.,
RA   Rinaldi M.M., Carella M., Marino B., Pizzuti A., Digilio M.C.,
RA   Tartaglia M., Dallapiccola B.;
RT   "NF1 gene mutations represent the major molecular event underlying
RT   neurofibromatosis-Noonan syndrome.";
RL   Am. J. Hum. Genet. 77:1092-1101(2005).
RN   [74]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-1187; LEU-1951 AND ARG-2745.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [75]
RP   VARIANT NF1 MET-991 DEL.
RX   PubMed=17160901; DOI=10.1086/510781;
RA   Upadhyaya M., Huson S.M., Davies M., Thomas N., Chuzhanova N.,
RA   Giovannini S., Evans D.G., Howard E., Kerr B., Griffiths S.,
RA   Consoli C., Side L., Adams D., Pierpont M., Hachen R., Barnicoat A.,
RA   Li H., Wallace P., Van Biervliet J.P., Stevenson D., Viskochil D.,
RA   Baralle D., Haan E., Riccardi V., Turnpenny P., Lazaro C.,
RA   Messiaen L.;
RT   "An absence of cutaneous neurofibromas associated with a 3-bp inframe
RT   deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of
RT   a clinically significant NF1 genotype-phenotype correlation.";
RL   Am. J. Hum. Genet. 80:140-151(2007).
RN   [76]
RP   VARIANT NFNS PHE-1411.
RX   PubMed=19845691; DOI=10.1111/j.1399-0004.2009.01233.x;
RA   Nystrom A.M., Ekvall S., Allanson J., Edeby C., Elinder M.,
RA   Holmstrom G., Bondeson M.L., Anneren G.;
RT   "Noonan syndrome and neurofibromatosis type I in a family with a novel
RT   mutation in NF1.";
RL   Clin. Genet. 76:524-534(2009).
RN   [77]
RP   VARIANT NF1 THR-160.
RX   PubMed=21838856; DOI=10.1186/1897-4287-9-6;
RA   Ponti G., Losi L., Martorana D., Priola M., Boni E., Pollio A.,
RA   Neri T.M., Seidenari S.;
RT   "Clinico-pathological and biomolecular findings in Italian patients
RT   with multiple cutaneous neurofibromas.";
RL   Hered. Cancer Clin. Pract. 9:6-6(2011).
RN   [78]
RP   VARIANTS GLU-176; THR-330; ASP-393; LEU-393; PRO-519; THR-776 AND
RP   PHE-1484.
RX   PubMed=22108604; DOI=10.1038/ejhg.2011.207;
RA   Thomas L., Spurlock G., Eudall C., Thomas N.S., Mort M., Hamby S.E.,
RA   Chuzhanova N., Brems H., Legius E., Cooper D.N., Upadhyaya M.;
RT   "Exploring the somatic NF1 mutational spectrum associated with NF1
RT   cutaneous neurofibromas.";
RL   Eur. J. Hum. Genet. 20:411-419(2012).
RN   [79]
RP   VARIANTS NF1 TRP-93; ARG-1048; ARG-1189; ARG-1661 (ISOFORM 1) AND
RP   THR-1918 (ISOFORM 1).
RX   PubMed=23758643; DOI=10.1111/ahg.12026;
RA   Nemethova M., Bolcekova A., Ilencikova D., Durovcikova D.,
RA   Hlinkova K., Hlavata A., Kovacs L., Kadasi L., Zatkova A.;
RT   "Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified
RT   in Slovak patients.";
RL   Ann. Hum. Genet. 77:364-379(2013).
RN   [80]
RP   VARIANT NF1 PRO-2125.
RX   PubMed=24413922; DOI=10.1007/s00381-013-2352-9;
RA   Ben-Salem S., Al-Shamsi A.M., Ali B.R., Al-Gazali L.;
RT   "The mutational spectrum of the NF1 gene in neurofibromatosis type I
RT   patients from UAE.";
RL   Childs Nerv. Syst. 30:1183-1189(2014).
CC   -!- FUNCTION: Stimulates the GTPase activity of Ras. NF1 shows greater
CC       affinity for Ras GAP, but lower specific activity. May be a
CC       regulator of Ras activity. {ECO:0000269|PubMed:2121371,
CC       ECO:0000269|PubMed:8417346}.
CC   -!- SUBUNIT: Interacts with HTR6 (PubMed:23027611).
CC       {ECO:0000269|PubMed:23027611}.
CC   -!- INTERACTION:
CC       P05067:APP; NbExp=3; IntAct=EBI-1172917, EBI-77613;
CC       P01112:HRAS; NbExp=2; IntAct=EBI-1172917, EBI-350145;
CC       P34741:SDC2; NbExp=4; IntAct=EBI-1172917, EBI-1172957;
CC       Q7Z699:SPRED1; NbExp=6; IntAct=EBI-1172917, EBI-5235340;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14988005}.
CC       Nucleus, nucleolus {ECO:0000269|PubMed:14988005}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Experimental confirmation may be lacking for some
CC         isoforms.;
CC       Name=2; Synonyms=Type II;
CC         IsoId=P21359-1; Sequence=Displayed;
CC       Name=1; Synonyms=Type I;
CC         IsoId=P21359-2; Sequence=VSP_001628;
CC         Note=Variant in position: 1661:C->R (in NF1). Variant in
CC         position: 1918:I->T (in NF1). {ECO:0000269|PubMed:23758643};
CC       Name=3;
CC         IsoId=P21359-3; Sequence=VSP_001629, VSP_001630;
CC       Name=4;
CC         IsoId=P21359-4; Sequence=VSP_001631, VSP_001632;
CC       Name=5;
CC         IsoId=P21359-5; Sequence=VSP_043467, VSP_043468;
CC       Name=6;
CC         IsoId=P21359-6; Sequence=VSP_001628, VSP_053587;
CC   -!- TISSUE SPECIFICITY: Detected in brain, peripheral nerve, lung,
CC       colon and muscle. {ECO:0000269|PubMed:8417346}.
CC   -!- DOMAIN: Binds phospholipids via its C-terminal CRAL-TRIO domain.
CC       Binds primarily glycerophospholipids with monounsaturated C18:1
CC       and/or C16:1 fatty acid moieties and a phosphatidylethanolamine or
CC       phosphatidylcholine headgroup. Has lesser affinity for lipids
CC       containing phosphatidylserine and phosphatidylinositol.
CC       {ECO:0000269|PubMed:16397625, ECO:0000269|PubMed:17187824,
CC       ECO:0000269|PubMed:21089070}.
CC   -!- RNA EDITING: Modified_positions=1306 {ECO:0000269|PubMed:11727199,
CC       ECO:0000269|PubMed:8602361}; Note=The stop codon (UGA) at position
CC       1306 is created by RNA editing. Various levels of RNA editing
CC       occurs in peripheral nerve-sheath tumor samples (PNSTs) from
CC       patients with NF1. Preferentially observed in transcripts
CC       containing exon 23A.;
CC   -!- DISEASE: Neurofibromatosis 1 (NF1) [MIM:162200]: A disease
CC       characterized by patches of skin pigmentation (cafe-au-lait
CC       spots), Lisch nodules of the iris, tumors in the peripheral
CC       nervous system and fibromatous skin tumors. Individuals with the
CC       disorder have increased susceptibility to the development of
CC       benign and malignant tumors. {ECO:0000269|PubMed:10220149,
CC       ECO:0000269|PubMed:10336779, ECO:0000269|PubMed:10607834,
CC       ECO:0000269|PubMed:10712197, ECO:0000269|PubMed:10980545,
CC       ECO:0000269|PubMed:11258625, ECO:0000269|PubMed:11735023,
CC       ECO:0000269|PubMed:11857752, ECO:0000269|PubMed:12522551,
CC       ECO:0000269|PubMed:12552569, ECO:0000269|PubMed:12746402,
CC       ECO:0000269|PubMed:1302608, ECO:0000269|PubMed:15060124,
CC       ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:15520408,
CC       ECO:0000269|PubMed:15523642, ECO:0000269|PubMed:15948193,
CC       ECO:0000269|PubMed:17160901, ECO:0000269|PubMed:21089070,
CC       ECO:0000269|PubMed:2114220, ECO:0000269|PubMed:21838856,
CC       ECO:0000269|PubMed:23758643, ECO:0000269|PubMed:24413922,
CC       ECO:0000269|PubMed:7981679, ECO:0000269|PubMed:8081387,
CC       ECO:0000269|PubMed:8544190, ECO:0000269|PubMed:8807336,
CC       ECO:0000269|PubMed:8834249, ECO:0000269|PubMed:9003501,
CC       ECO:0000269|PubMed:9101300, ECO:0000269|PubMed:9150739,
CC       ECO:0000269|PubMed:9298829, ECO:0000269|PubMed:9668168}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An
CC       aggressive pediatric myelodysplastic syndrome/myeloproliferative
CC       disorder characterized by malignant transformation in the
CC       hematopoietic stem cell compartment with proliferation of
CC       differentiated progeny. Patients have splenomegaly, enlarged lymph
CC       nodes, rashes, and hemorrhages. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Watson syndrome (WTSN) [MIM:193520]: A syndrome
CC       characterized by the presence of pulmonary stenosis, cafe-au-lait
CC       spots, and mental retardation. It is considered as an atypical
CC       form of neurofibromatosis. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Familial spinal neurofibromatosis (FSNF) [MIM:162210]:
CC       Considered to be an alternative form of neurofibromatosis, showing
CC       multiple spinal tumors. {ECO:0000269|PubMed:11704931}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]:
CC       Characterized by manifestations of both NF1 and Noonan syndrome
CC       (NS). NS is a disorder characterized by dysmorphic facial
CC       features, short stature, hypertelorism, cardiac anomalies,
CC       deafness, motor delay, and a bleeding diathesis.
CC       {ECO:0000269|PubMed:12707950, ECO:0000269|PubMed:16380919,
CC       ECO:0000269|PubMed:19845691}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       Note=The gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- CAUTION: Was originally thought to be associated with LEOPARD
CC       (LS), an autosomal dominant syndrome.
CC       {ECO:0000305|PubMed:8807336}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59923.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NF1ID134.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nf1/";
CC   -!- WEB RESOURCE: Name=Mendelian genes neurofibromin 1 (NF1);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/NF1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; M89914; AAA59925.1; -; mRNA.
DR   EMBL; M82814; AAA59924.1; -; mRNA.
DR   EMBL; M60496; AAA59928.1; -; mRNA.
DR   EMBL; D12625; BAA02150.1; -; mRNA.
DR   EMBL; M38106; AAA74897.1; -; mRNA.
DR   EMBL; M38107; AAB59558.1; -; mRNA.
DR   EMBL; D42072; BAA07669.1; -; mRNA.
DR   EMBL; AY796305; AAV50004.1; -; Genomic_DNA.
DR   EMBL; AC004222; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC134669; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC135724; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC138207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC139072; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471147; EAW80272.1; -; Genomic_DNA.
DR   EMBL; CH471147; EAW80275.1; -; Genomic_DNA.
DR   EMBL; AH000834; AAA18483.1; -; Genomic_DNA.
DR   EMBL; Y07853; CAA69179.1; -; Genomic_DNA.
DR   EMBL; U17690; AAB48380.1; -; Genomic_DNA.
DR   EMBL; U17680; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17681; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17682; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17683; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17684; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17685; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17686; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17687; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17688; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17689; AAB48380.1; JOINED; Genomic_DNA.
DR   EMBL; U17690; AAB48379.1; -; Genomic_DNA.
DR   EMBL; U17680; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17681; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17682; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17683; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17684; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17685; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17687; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17688; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17689; AAB48379.1; JOINED; Genomic_DNA.
DR   EMBL; U17656; AAB48373.1; -; Genomic_DNA.
DR   EMBL; U17659; AAB48374.1; -; Genomic_DNA.
DR   EMBL; U17662; AAB48375.1; -; Genomic_DNA.
DR   EMBL; U17668; AAB48376.1; -; Genomic_DNA.
DR   EMBL; U17667; AAB48376.1; JOINED; Genomic_DNA.
DR   EMBL; U17673; AAB48377.1; -; Genomic_DNA.
DR   EMBL; U17677; AAB48378.1; -; Genomic_DNA.
DR   EMBL; U17676; AAB48378.1; JOINED; Genomic_DNA.
DR   EMBL; M60915; AAA59921.1; -; mRNA.
DR   EMBL; M60915; AAA59922.1; -; mRNA.
DR   EMBL; M61213; AAA59923.1; ALT_INIT; mRNA.
DR   EMBL; S51751; AAB24636.1; -; mRNA.
DR   EMBL; D10490; BAA01371.1; -; mRNA.
DR   CCDS; CCDS11264.1; -. [P21359-2]
DR   CCDS; CCDS42292.1; -. [P21359-1]
DR   CCDS; CCDS45645.1; -. [P21359-5]
DR   PIR; B55282; B55282.
DR   PIR; I78852; I78852.
DR   RefSeq; NP_000258.1; NM_000267.3. [P21359-2]
DR   RefSeq; NP_001035957.1; NM_001042492.2. [P21359-1]
DR   RefSeq; NP_001121619.1; NM_001128147.2. [P21359-5]
DR   PDB; 1NF1; X-ray; 2.50 A; A=1198-1551.
DR   PDB; 2D4Q; X-ray; 2.30 A; A/B=1581-1837.
DR   PDB; 2E2X; X-ray; 2.50 A; A/B=1566-1837.
DR   PDB; 3P7Z; X-ray; 2.65 A; A/B=1566-1837.
DR   PDB; 3PEG; X-ray; 2.52 A; A=1566-1837.
DR   PDB; 3PG7; X-ray; 2.19 A; A/B=1581-1837.
DR   PDBsum; 1NF1; -.
DR   PDBsum; 2D4Q; -.
DR   PDBsum; 2E2X; -.
DR   PDBsum; 3P7Z; -.
DR   PDBsum; 3PEG; -.
DR   PDBsum; 3PG7; -.
DR   SMR; P21359; -.
DR   BioGrid; 110836; 120.
DR   IntAct; P21359; 29.
DR   MINT; P21359; -.
DR   STRING; 9606.ENSP00000351015; -.
DR   iPTMnet; P21359; -.
DR   PhosphoSitePlus; P21359; -.
DR   BioMuta; NF1; -.
DR   DMDM; 548350; -.
DR   EPD; P21359; -.
DR   jPOST; P21359; -.
DR   MassIVE; P21359; -.
DR   MaxQB; P21359; -.
DR   PaxDb; P21359; -.
DR   PeptideAtlas; P21359; -.
DR   PRIDE; P21359; -.
DR   ProteomicsDB; 53861; -. [P21359-1]
DR   ProteomicsDB; 53862; -. [P21359-2]
DR   ProteomicsDB; 53863; -. [P21359-3]
DR   ProteomicsDB; 53864; -. [P21359-4]
DR   ProteomicsDB; 53865; -. [P21359-5]
DR   Ensembl; ENST00000356175; ENSP00000348498; ENSG00000196712. [P21359-2]
DR   Ensembl; ENST00000358273; ENSP00000351015; ENSG00000196712. [P21359-1]
DR   Ensembl; ENST00000431387; ENSP00000412921; ENSG00000196712. [P21359-5]
DR   Ensembl; ENST00000487476; ENSP00000491589; ENSG00000196712. [P21359-3]
DR   GeneID; 4763; -.
DR   KEGG; hsa:4763; -.
DR   UCSC; uc002hgf.3; human. [P21359-1]
DR   CTD; 4763; -.
DR   DisGeNET; 4763; -.
DR   GeneCards; NF1; -.
DR   GeneReviews; NF1; -.
DR   HGNC; HGNC:7765; NF1.
DR   HPA; HPA045502; -.
DR   MalaCards; NF1; -.
DR   MIM; 114500; phenotype.
DR   MIM; 162200; phenotype.
DR   MIM; 162210; phenotype.
DR   MIM; 193520; phenotype.
DR   MIM; 601321; phenotype.
DR   MIM; 607785; phenotype.
DR   MIM; 613113; gene.
DR   neXtProt; NX_P21359; -.
DR   OpenTargets; ENSG00000196712; -.
DR   Orphanet; 97685; 17q11 microdeletion syndrome.
DR   Orphanet; 139474; 17q11.2 microduplication syndrome.
DR   Orphanet; 86834; Juvenile myelomonocytic leukemia.
DR   Orphanet; 363700; Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion.
DR   Orphanet; 638; Neurofibromatosis-Noonan syndrome.
DR   PharmGKB; PA31572; -.
DR   eggNOG; KOG1826; Eukaryota.
DR   eggNOG; ENOG410XRPJ; LUCA.
DR   GeneTree; ENSGT00550000074797; -.
DR   HOGENOM; HOG000047020; -.
DR   InParanoid; P21359; -.
DR   KO; K08052; -.
DR   OMA; VITRMCR; -.
DR   OrthoDB; 1487465at2759; -.
DR   PhylomeDB; P21359; -.
DR   TreeFam; TF300302; -.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants.
DR   SignaLink; P21359; -.
DR   SIGNOR; P21359; -.
DR   ChiTaRS; NF1; human.
DR   EvolutionaryTrace; P21359; -.
DR   GeneWiki; Neurofibromin_1; -.
DR   GenomeRNAi; 4763; -.
DR   Pharos; P21359; -.
DR   PRO; PR:P21359; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000196712; Expressed in 224 organ(s), highest expression level in kidney.
DR   ExpressionAtlas; P21359; baseline and differential.
DR   Genevisible; P21359; HS.
DR   GO; GO:0030424; C:axon; IDA:HGNC-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:HGNC-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IDA:HGNC-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; ISS:HGNC-UCL.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB.
DR   GO; GO:0031210; F:phosphatidylcholine binding; IDA:UniProtKB.
DR   GO; GO:0008429; F:phosphatidylethanolamine binding; IDA:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:HGNC-UCL.
DR   GO; GO:0030325; P:adrenal gland development; ISS:HGNC-UCL.
DR   GO; GO:0021764; P:amygdala development; IEA:Ensembl.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:HGNC-UCL.
DR   GO; GO:0007420; P:brain development; ISS:HGNC-UCL.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; ISS:HGNC-UCL.
DR   GO; GO:0007154; P:cell communication; ISS:HGNC-UCL.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:HGNC-UCL.
DR   GO; GO:0050890; P:cognition; IMP:HGNC-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:HGNC-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; ISS:HGNC-UCL.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0021897; P:forebrain astrocyte development; ISS:HGNC-UCL.
DR   GO; GO:0048853; P:forebrain morphogenesis; ISS:HGNC-UCL.
DR   GO; GO:0061534; P:gamma-aminobutyric acid secretion, neurotransmission; IEA:Ensembl.
DR   GO; GO:0061535; P:glutamate secretion, neurotransmission; IEA:Ensembl.
DR   GO; GO:0048820; P:hair follicle maturation; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; ISS:HGNC-UCL.
DR   GO; GO:0001889; P:liver development; ISS:HGNC-UCL.
DR   GO; GO:0000165; P:MAPK cascade; ISS:HGNC-UCL.
DR   GO; GO:0001656; P:metanephros development; ISS:HGNC-UCL.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; ISS:HGNC-UCL.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:MGI.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:HGNC-UCL.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:HGNC-UCL.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:MGI.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; ISS:HGNC-UCL.
DR   GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:Ensembl.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:HGNC-UCL.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0042308; P:negative regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; ISS:HGNC-UCL.
DR   GO; GO:0035021; P:negative regulation of Rac protein signal transduction; IEA:Ensembl.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0098597; P:observational learning; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:HGNC-UCL.
DR   GO; GO:0007422; P:peripheral nervous system development; ISS:HGNC-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; ISS:HGNC-UCL.
DR   GO; GO:0043473; P:pigmentation; ISS:HGNC-UCL.
DR   GO; GO:0045762; P:positive regulation of adenylate cyclase activity; ISS:HGNC-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:HGNC-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:HGNC-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; ISS:HGNC-UCL.
DR   GO; GO:0045765; P:regulation of angiogenesis; IMP:HGNC-UCL.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; IMP:HGNC-UCL.
DR   GO; GO:0045124; P:regulation of bone resorption; ISS:HGNC-UCL.
DR   GO; GO:0001952; P:regulation of cell-matrix adhesion; ISS:HGNC-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045685; P:regulation of glial cell differentiation; ISS:HGNC-UCL.
DR   GO; GO:0043087; P:regulation of GTPase activity; IMP:HGNC-UCL.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:1900271; P:regulation of long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; ISS:HGNC-UCL.
DR   GO; GO:0014044; P:Schwann cell development; ISS:HGNC-UCL.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0048745; P:smooth muscle tissue development; ISS:HGNC-UCL.
DR   GO; GO:0021510; P:spinal cord development; ISS:HGNC-UCL.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:HGNC-UCL.
DR   GO; GO:0008542; P:visual learning; ISS:HGNC-UCL.
DR   GO; GO:0042060; P:wound healing; ISS:HGNC-UCL.
DR   CDD; cd00170; SEC14; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.40.525.10; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR001251; CRAL-TRIO_dom.
DR   InterPro; IPR036865; CRAL-TRIO_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR039360; Ras_GTPase.
DR   InterPro; IPR023152; RasGAP_CS.
DR   InterPro; IPR001936; RasGAP_dom.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   PANTHER; PTHR10194; PTHR10194; 1.
DR   Pfam; PF13716; CRAL_TRIO_2; 1.
DR   Pfam; PF00616; RasGAP; 1.
DR   SMART; SM00323; RasGAP; 1.
DR   SMART; SM00516; SEC14; 1.
DR   SUPFAM; SSF48350; SSF48350; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1.
DR   PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; GTPase activation; Lipid-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; RNA editing;
KW   Tumor suppressor.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P97526}.
FT   CHAIN         2   2839       Neurofibromin.
FT                                /FTId=PRO_0000010773.
FT   CHAIN         2   1305       Neurofibromin truncated.
FT                                /FTId=PRO_0000010774.
FT   DOMAIN     1235   1451       Ras-GAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00167}.
FT   DOMAIN     1580   1738       CRAL-TRIO. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00056}.
FT   REGION     1580   1837       Lipid binding.
FT   MOTIF      2555   2571       Bipartite nuclear localization signal.
FT   COMPBIAS   1352   1355       Poly-Ser.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P97526}.
FT   MOD_RES     864    864       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     876    876       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2188   2188       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2467   2467       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q04690}.
FT   MOD_RES    2514   2514       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q04690}.
FT   MOD_RES    2515   2515       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2521   2521       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2523   2523       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2543   2543       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2565   2565       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2597   2597       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2802   2802       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2817   2817       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     548    551       ALLV -> VRGK (in isoform 3).
FT                                {ECO:0000303|PubMed:1339276}.
FT                                /FTId=VSP_001629.
FT   VAR_SEQ     552   2839       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:1339276}.
FT                                /FTId=VSP_001630.
FT   VAR_SEQ     574    593       SSQMLFYICKKLTSHQMLSS -> RYMYFYFLNSTFKFYFV
FT                                FLS (in isoform 5).
FT                                {ECO:0000303|PubMed:7570581}.
FT                                /FTId=VSP_043467.
FT   VAR_SEQ     594   2839       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:7570581}.
FT                                /FTId=VSP_043468.
FT   VAR_SEQ    1371   1391       Missing (in isoform 1 and isoform 6).
FT                                {ECO:0000303|PubMed:1457041,
FT                                ECO:0000303|PubMed:1783401,
FT                                ECO:0000303|PubMed:1923522,
FT                                ECO:0000303|PubMed:2114220,
FT                                ECO:0000303|PubMed:2116237,
FT                                ECO:0000303|PubMed:2134734}.
FT                                /FTId=VSP_001628.
FT   VAR_SEQ    1591   1598       SIFYQAGT -> TPPPEPET (in isoform 4).
FT                                {ECO:0000303|PubMed:2121370}.
FT                                /FTId=VSP_001631.
FT   VAR_SEQ    1599   2839       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:2121370}.
FT                                /FTId=VSP_001632.
FT   VAR_SEQ    2792   2792       P -> PASLPCSNSAVFMQLFPHQ (in isoform 6).
FT                                {ECO:0000303|PubMed:2116237}.
FT                                /FTId=VSP_053587.
FT   VARIANT      31     31       H -> R (in NF1; dbSNP:rs199474725).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032459.
FT   VARIANT      74     74       A -> D (in mismatch repair deficient
FT                                cancer cells; dbSNP:rs199474726).
FT                                {ECO:0000269|PubMed:12522551}.
FT                                /FTId=VAR_017550.
FT   VARIANT      80     80       Y -> C (in dbSNP:rs4795581).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022254.
FT   VARIANT      80     80       Y -> S (in dbSNP:rs4795581).
FT                                /FTId=VAR_049135.
FT   VARIANT      82     82       S -> F (in NF1; dbSNP:rs199474729).
FT                                {ECO:0000269|PubMed:11857752}.
FT                                /FTId=VAR_021730.
FT   VARIANT      93     93       C -> W (in NF1).
FT                                {ECO:0000269|PubMed:23758643}.
FT                                /FTId=VAR_071668.
FT   VARIANT      93     93       C -> Y (in NF1; dbSNP:rs199474728).
FT                                {ECO:0000269|PubMed:12522551}.
FT                                /FTId=VAR_017551.
FT   VARIANT     117    117       I -> S (in NF1; dbSNP:rs199474731).
FT                                {ECO:0000269|PubMed:10607834}.
FT                                /FTId=VAR_010989.
FT   VARIANT     145    145       L -> P (in NF1; dbSNP:rs199474734).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032460.
FT   VARIANT     157    157       I -> N (in NF1; dbSNP:rs199474744).
FT                                {ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021731.
FT   VARIANT     160    160       R -> T (in NF1; dbSNP:rs199474752).
FT                                {ECO:0000269|PubMed:21838856}.
FT                                /FTId=VAR_065888.
FT   VARIANT     176    176       D -> E (found in mismatch repair
FT                                deficient cancer cells; also found in a
FT                                cutaneous neurofibroma from a patient
FT                                with neurofibromatosis; somatic mutation;
FT                                dbSNP:rs112306990).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:12522551,
FT                                ECO:0000269|PubMed:15060124,
FT                                ECO:0000269|PubMed:15146469,
FT                                ECO:0000269|PubMed:22108604}.
FT                                /FTId=VAR_017552.
FT   VARIANT     186    186       D -> V (in NF1; reduced splicing
FT                                enhancement).
FT                                {ECO:0000269|PubMed:15523642}.
FT                                /FTId=VAR_032461.
FT   VARIANT     194    194       L -> R (in NFNS; dbSNP:rs199474753).
FT                                {ECO:0000269|PubMed:16380919}.
FT                                /FTId=VAR_032462.
FT   VARIANT     216    216       L -> P (in NF1; dbSNP:rs199474756).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021732.
FT   VARIANT     324    324       C -> R (in NF1; dbSNP:rs199474735).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032463.
FT   VARIANT     330    330       A -> T (in a cutaneous neurofibroma from
FT                                a patient with neurofibromatosis; somatic
FT                                mutation; dbSNP:rs199474767).
FT                                {ECO:0000269|PubMed:22108604}.
FT                                /FTId=VAR_067201.
FT   VARIANT     337    337       E -> V (in NF1; dbSNP:rs199474736).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032464.
FT   VARIANT     338    338       D -> G (in NF1; dbSNP:rs199474773).
FT                                {ECO:0000269|PubMed:9298829}.
FT                                /FTId=VAR_010990.
FT   VARIANT     357    357       L -> P (in NF1; dbSNP:rs137854563).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021733.
FT   VARIANT     393    393       H -> D (in a cutaneous neurofibroma from
FT                                a patient with neurofibromatosis; somatic
FT                                mutation; dbSNP:rs199474768).
FT                                {ECO:0000269|PubMed:22108604}.
FT                                /FTId=VAR_067202.
FT   VARIANT     393    393       H -> L (in a cutaneous neurofibroma from
FT                                a patient with neurofibromatosis; somatic
FT                                mutation; dbSNP:rs199474769).
FT                                {ECO:0000269|PubMed:22108604}.
FT                                /FTId=VAR_067203.
FT   VARIANT     489    489       Y -> C (in NF1; dbSNP:rs137854557).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032465.
FT   VARIANT     491    491       Y -> C (in NF1; dbSNP:rs199474757).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021734.
FT   VARIANT     508    508       L -> P (in NF1; dbSNP:rs137854558).
FT                                {ECO:0000269|PubMed:11258625}.
FT                                /FTId=VAR_010991.
FT   VARIANT     519    519       Q -> P (in a cutaneous neurofibroma from
FT                                a patient with neurofibromatosis; somatic
FT                                mutation; dbSNP:rs199474770).
FT                                {ECO:0000269|PubMed:22108604}.
FT                                /FTId=VAR_067204.
FT   VARIANT     532    532       L -> P (in NF1; dbSNP:rs199474737).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032466.
FT   VARIANT     549    549       L -> P (in NF1; dbSNP:rs199474758).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021735.
FT   VARIANT     574    574       S -> R (in NF1).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032467.
FT   VARIANT     578    578       L -> R (in NF1; dbSNP:rs199474774).
FT                                {ECO:0000269|PubMed:12746402}.
FT                                /FTId=VAR_021736.
FT   VARIANT     581    581       I -> T (in NF1; dbSNP:rs199474759).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021737.
FT   VARIANT     583    583       K -> R (in NF1; dbSNP:rs199474760).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021738.
FT   VARIANT     604    604       L -> V (in NF1; dbSNP:rs142712751).
FT                                {ECO:0000269|PubMed:12522551}.
FT                                /FTId=VAR_017553.
FT   VARIANT     629    629       G -> R (in NF1; affects splicing by
FT                                creating a novel splice acceptor site;
FT                                dbSNP:rs199474738).
FT                                {ECO:0000269|PubMed:15060124,
FT                                ECO:0000269|PubMed:15146469,
FT                                ECO:0000269|PubMed:8834249}.
FT                                /FTId=VAR_002653.
FT   VARIANT     665    665       S -> F (in NF1; unknown pathological
FT                                significance; dbSNP:rs145891889).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_021739.
FT   VARIANT     678    678       P -> L (in dbSNP:rs17881753).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022255.
FT   VARIANT     695    695       L -> P (in NF1; dbSNP:rs199474761).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021740.
FT   VARIANT     712    712       H -> R (in mismatch repair deficient
FT                                cancer cells; dbSNP:rs199474727).
FT                                {ECO:0000269|PubMed:12522551}.
FT                                /FTId=VAR_017554.
FT   VARIANT     763    763       L -> P (in NF1; dbSNP:rs199474762).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021741.
FT   VARIANT     765    765       R -> H (in NF1; unknown pathological
FT                                significance; dbSNP:rs199474777).
FT                                {ECO:0000269|PubMed:10336779}.
FT                                /FTId=VAR_021742.
FT   VARIANT     776    776       A -> T (in a cutaneous neurofibroma from
FT                                a patient with neurofibromatosis; somatic
FT                                mutation; dbSNP:rs199474771).
FT                                {ECO:0000269|PubMed:22108604}.
FT                                /FTId=VAR_067205.
FT   VARIANT     777    777       W -> S (in NF1; dbSNP:rs199474745).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021743.
FT   VARIANT     780    780       T -> K (in NF1; dbSNP:rs199474746).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:11735023,
FT                                ECO:0000269|PubMed:12552569,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021744.
FT   VARIANT     781    781       H -> P (in NF1; dbSNP:rs199474763).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021745.
FT   VARIANT     784    784       W -> C (in NF1; dbSNP:rs199474778).
FT                                {ECO:0000269|PubMed:11735023}.
FT                                /FTId=VAR_021746.
FT   VARIANT     784    784       W -> R (in NF1; dbSNP:rs199474730).
FT                                {ECO:0000269|PubMed:11857752,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021747.
FT   VARIANT     844    844       L -> F (in NF1; dbSNP:rs199474785).
FT                                {ECO:0000269|PubMed:10980545,
FT                                ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_010992.
FT   VARIANT     844    844       L -> P (in NF1; dbSNP:rs137854566).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032468.
FT   VARIANT     844    844       L -> R (in NF1; sporadic;
FT                                dbSNP:rs137854566).
FT                                {ECO:0000269|PubMed:12522551,
FT                                ECO:0000269|PubMed:15948193,
FT                                ECO:0000269|PubMed:9150739}.
FT                                /FTId=VAR_002654.
FT   VARIANT     847    847       L -> P (in NF1; dbSNP:rs199474747).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:12552569,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021748.
FT   VARIANT     848    848       G -> E (in NF1; dbSNP:rs199474748).
FT                                {ECO:0000269|PubMed:12552569,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021749.
FT   VARIANT     873    873       R -> C (in dbSNP:rs199474739).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032469.
FT   VARIANT     898    898       L -> P (in NF1; sporadic;
FT                                dbSNP:rs199474786).
FT                                {ECO:0000269|PubMed:12522551,
FT                                ECO:0000269|PubMed:9150739}.
FT                                /FTId=VAR_002655.
FT   VARIANT     920    920       L -> P (in NF1; patient with cafe-au-lait
FT                                spots; may be a distinct form of NF1;
FT                                dbSNP:rs199474775).
FT                                {ECO:0000269|PubMed:12746402}.
FT                                /FTId=VAR_021750.
FT   VARIANT     968    968       M -> R (in NF1; dbSNP:rs199474749).
FT                                {ECO:0000269|PubMed:12552569,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021751.
FT   VARIANT     991    991       Missing (in NF1; most patients carrying
FT                                the mutation do not manifest cutaneous
FT                                neurofibromas).
FT                                {ECO:0000269|PubMed:15060124,
FT                                ECO:0000269|PubMed:17160901,
FT                                ECO:0000269|PubMed:7904209}.
FT                                /FTId=VAR_002656.
FT   VARIANT    1035   1035       M -> R (in NF1; dbSNP:rs137854553).
FT                                {ECO:0000269|PubMed:8807336}.
FT                                /FTId=VAR_002657.
FT   VARIANT    1048   1048       W -> R (in NF1).
FT                                {ECO:0000269|PubMed:23758643}.
FT                                /FTId=VAR_071669.
FT   VARIANT    1073   1073       M -> V (in NF1; dbSNP:rs199474740).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032470.
FT   VARIANT    1147   1147       L -> P (in NF1; dbSNP:rs199474779).
FT                                {ECO:0000269|PubMed:11735023}.
FT                                /FTId=VAR_021752.
FT   VARIANT    1156   1156       N -> S (in NF1; dbSNP:rs199474764).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021753.
FT   VARIANT    1166   1166       G -> D (in NF1; dbSNP:rs199474787).
FT                                {ECO:0000269|PubMed:7981679}.
FT                                /FTId=VAR_010993.
FT   VARIANT    1187   1187       L -> I (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035543.
FT   VARIANT    1189   1189       Q -> R (in NF1; dbSNP:rs752039618).
FT                                {ECO:0000269|PubMed:23758643}.
FT                                /FTId=VAR_071670.
FT   VARIANT    1193   1193       F -> C (in NF1; dbSNP:rs199474780).
FT                                {ECO:0000269|PubMed:11735023}.
FT                                /FTId=VAR_021754.
FT   VARIANT    1196   1196       L -> R (in NF1; dbSNP:rs199474741).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032471.
FT   VARIANT    1204   1204       R -> G (in NF1; dbSNP:rs199474732).
FT                                {ECO:0000269|PubMed:10336779}.
FT                                /FTId=VAR_021755.
FT   VARIANT    1204   1204       R -> W (in NF1; dbSNP:rs199474732).
FT                                {ECO:0000269|PubMed:10607834}.
FT                                /FTId=VAR_010994.
FT   VARIANT    1243   1243       L -> P (in NF1; with neurofibromatous
FT                                neuropathy; dbSNP:rs137854564).
FT                                {ECO:0000269|PubMed:15520408}.
FT                                /FTId=VAR_032472.
FT   VARIANT    1250   1250       R -> P (in NF1; dbSNP:rs199474765).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021756.
FT   VARIANT    1276   1276       R -> G (in NF1; dbSNP:rs199474742).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032473.
FT   VARIANT    1276   1276       R -> P (in NF1; complete loss of GAP
FT                                activity; dbSNP:rs137854556).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:9668168}.
FT                                /FTId=VAR_010995.
FT   VARIANT    1276   1276       R -> Q (in NF1 and mismatch repair
FT                                deficient cancer cells;
FT                                dbSNP:rs137854556).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:12522551,
FT                                ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_017555.
FT   VARIANT    1411   1411       L -> F (in NFNS; dbSNP:rs199474789).
FT                                {ECO:0000269|PubMed:19845691}.
FT                                /FTId=VAR_065236.
FT   VARIANT    1412   1412       R -> S (in NF1; significant reduction of
FT                                GAP activity; dbSNP:rs137854554).
FT                                {ECO:0000269|PubMed:9003501}.
FT                                /FTId=VAR_010996.
FT   VARIANT    1422   1422       Y -> H (in dbSNP:rs17884349).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022256.
FT   VARIANT    1430   1430       K -> E (in NF1).
FT                                {ECO:0000269|PubMed:15060124}.
FT                                /FTId=VAR_032474.
FT   VARIANT    1440   1440       K -> Q (in NF1; dbSNP:rs199474790).
FT                                {ECO:0000269|PubMed:9003501}.
FT                                /FTId=VAR_010997.
FT   VARIANT    1440   1440       K -> R (in NF1; dbSNP:rs199474788).
FT                                {ECO:0000269|PubMed:7981679}.
FT                                /FTId=VAR_002658.
FT   VARIANT    1444   1444       K -> E (in NF1 and NFNS; significant
FT                                reduction of intrinsic GAP activity;
FT                                dbSNP:rs137854550).
FT                                {ECO:0000269|PubMed:11857752,
FT                                ECO:0000269|PubMed:1568247,
FT                                ECO:0000269|PubMed:16380919,
FT                                ECO:0000269|PubMed:9003501}.
FT                                /FTId=VAR_002659.
FT   VARIANT    1444   1444       K -> N (in NF1; dbSNP:rs199474750).
FT                                {ECO:0000269|PubMed:12552569,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021757.
FT   VARIANT    1444   1444       K -> R (in NF1; dbSNP:rs199474781).
FT                                {ECO:0000269|PubMed:11735023}.
FT                                /FTId=VAR_021758.
FT   VARIANT    1446   1446       L -> P (in NF1; dbSNP:rs199474733).
FT                                {ECO:0000269|PubMed:10220149,
FT                                ECO:0000269|PubMed:10607834,
FT                                ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_008129.
FT   VARIANT    1451   1451       N -> T (in NFNS; dbSNP:rs199474754).
FT                                {ECO:0000269|PubMed:16380919}.
FT                                /FTId=VAR_032475.
FT   VARIANT    1453   1453       V -> L (in NFNS; dbSNP:rs199474755).
FT                                {ECO:0000269|PubMed:16380919}.
FT                                /FTId=VAR_032476.
FT   VARIANT    1459   1459       Missing (in NFNS).
FT                                {ECO:0000269|PubMed:12707950,
FT                                ECO:0000269|PubMed:15060124,
FT                                ECO:0000269|PubMed:16380919}.
FT                                /FTId=VAR_032477.
FT   VARIANT    1484   1484       S -> F (in a cutaneous neurofibroma from
FT                                a patient with neurofibromatosis; somatic
FT                                mutation; dbSNP:rs199474772).
FT                                {ECO:0000269|PubMed:22108604}.
FT                                /FTId=VAR_067206.
FT   VARIANT    1489   1489       S -> G (in NF1; dbSNP:rs199474743).
FT                                {ECO:0000269|PubMed:15060124,
FT                                ECO:0000269|PubMed:9003501}.
FT                                /FTId=VAR_010998.
FT   VARIANT    1605   1605       I -> V (in NF1; reduces protein
FT                                stability; dbSNP:rs199474766).
FT                                {ECO:0000269|PubMed:10712197,
FT                                ECO:0000269|PubMed:21089070}.
FT                                /FTId=VAR_021759.
FT   VARIANT    1611   1611       R -> W (in NF1; dbSNP:rs1060500316).
FT                                {ECO:0000269|PubMed:9298829}.
FT                                /FTId=VAR_002660.
FT   VARIANT    1733   1733       L -> LGHEQQKLPAATLAL (in NF1).
FT                                {ECO:0000269|PubMed:8317503}.
FT                                /FTId=VAR_002661.
FT   VARIANT    1785   1785       A -> S (in NF1; dbSNP:rs199474782).
FT                                {ECO:0000269|PubMed:11735023}.
FT                                /FTId=VAR_021760.
FT   VARIANT    1951   1951       P -> L (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035544.
FT   VARIANT    1952   1952       W -> R (in NF1; dbSNP:rs199474791).
FT                                {ECO:0000269|PubMed:9101300}.
FT                                /FTId=VAR_002662.
FT   VARIANT    1953   1953       L -> P (in NF1; dbSNP:rs199474792).
FT                                {ECO:0000269|PubMed:2114220}.
FT                                /FTId=VAR_002663.
FT   VARIANT    1953   1953       Missing (in NF1).
FT                                {ECO:0000269|PubMed:12552569,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021761.
FT   VARIANT    2001   2001       G -> R (in NF1; dbSNP:rs199474751).
FT                                {ECO:0000269|PubMed:12552569,
FT                                ECO:0000269|PubMed:15146469}.
FT                                /FTId=VAR_021762.
FT   VARIANT    2012   2012       D -> N (in NF1; dbSNP:rs199474783).
FT                                {ECO:0000269|PubMed:11735023}.
FT                                /FTId=VAR_021763.
FT   VARIANT    2088   2088       L -> P (in FSNF; no cafe-au-lait macules;
FT                                null mutation; 50% reduction of protein
FT                                level; dbSNP:rs137854561).
FT                                {ECO:0000269|PubMed:11704931}.
FT                                /FTId=VAR_017669.
FT   VARIANT    2125   2125       L -> P (in NF1).
FT                                {ECO:0000269|PubMed:24413922}.
FT                                /FTId=VAR_071671.
FT   VARIANT    2164   2164       L -> M (in NF1; dbSNP:rs137854551).
FT                                {ECO:0000269|PubMed:1302608}.
FT                                /FTId=VAR_002664.
FT   VARIANT    2192   2192       Y -> N (in NF1; dbSNP:rs267606598).
FT                                {ECO:0000269|PubMed:1302608}.
FT                                /FTId=VAR_002665.
FT   VARIANT    2221   2221       P -> A (in NF1; dbSNP:rs199474776).
FT                                {ECO:0000269|PubMed:12746402}.
FT                                /FTId=VAR_021764.
FT   VARIANT    2357   2357       E -> K (in NF1; dbSNP:rs199474784).
FT                                {ECO:0000269|PubMed:11735023}.
FT                                /FTId=VAR_021765.
FT   VARIANT    2387   2388       Missing (in NF1).
FT                                {ECO:0000269|PubMed:10607834,
FT                                ECO:0000269|PubMed:8081387}.
FT                                /FTId=VAR_002666.
FT   VARIANT    2507   2507       T -> I (in NF1; dbSNP:rs149055633).
FT                                {ECO:0000269|PubMed:10712197}.
FT                                /FTId=VAR_021766.
FT   VARIANT    2511   2511       V -> L (in dbSNP:rs2230850).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022257.
FT   VARIANT    2631   2631       T -> A (in NF1; dbSNP:rs199474793).
FT                                {ECO:0000269|PubMed:8544190}.
FT                                /FTId=VAR_002667.
FT   VARIANT    2745   2745       G -> R (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035545.
FT   MUTAGEN    1691   1691       K->A: Reduces phospholipid binding; when
FT                                associated with A-1695; A-1769 and A-
FT                                1771. {ECO:0000269|PubMed:16397625}.
FT   MUTAGEN    1695   1695       R->A: Reduces phospholipid binding; when
FT                                associated with A-1691; A-1769 and A-
FT                                1771. {ECO:0000269|PubMed:16397625}.
FT   MUTAGEN    1769   1769       R->A: Reduces phospholipid binding; when
FT                                associated with A-1691; A-1695 and A-
FT                                1771. {ECO:0000269|PubMed:16397625}.
FT   MUTAGEN    1771   1771       K->A: Reduces phospholipid binding; when
FT                                associated with A-1691; A-169 and A-1769.
FT                                {ECO:0000269|PubMed:16397625,
FT                                ECO:0000269|PubMed:21089070}.
FT   MUTAGEN    1771   1771       Missing: Reduces protein stability.
FT                                {ECO:0000269|PubMed:16397625,
FT                                ECO:0000269|PubMed:21089070}.
FT   CONFLICT    496    496       M -> I (in Ref. 11; AAA74897/AAB59558).
FT                                {ECO:0000305}.
FT   CONFLICT   1094   1095       EL -> ST (in Ref. 14; AAA59923).
FT                                {ECO:0000305}.
FT   CONFLICT   1576   1576       H -> HH (in Ref. 11; AAA74897/AAB59558).
FT                                {ECO:0000305}.
FT   HELIX      1208   1216       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1224   1228       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1233   1235       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1236   1248       {ECO:0000244|PDB:1NF1}.
FT   TURN       1249   1251       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1253   1263       {ECO:0000244|PDB:1NF1}.
FT   STRAND     1266   1270       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1282   1293       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1296   1299       {ECO:0000244|PDB:1NF1}.
FT   STRAND     1300   1302       {ECO:0000244|PDB:1NF1}.
FT   TURN       1335   1337       {ECO:0000244|PDB:1NF1}.
FT   TURN       1339   1342       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1343   1352       {ECO:0000244|PDB:1NF1}.
FT   TURN       1353   1356       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1361   1370       {ECO:0000244|PDB:1NF1}.
FT   TURN       1394   1396       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1402   1412       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1414   1419       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1434   1440       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1442   1451       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1462   1464       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1465   1470       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1472   1481       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1510   1514       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1517   1520       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1535   1544       {ECO:0000244|PDB:1NF1}.
FT   HELIX      1569   1578       {ECO:0000244|PDB:3P7Z}.
FT   TURN       1582   1586       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1587   1590       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1592   1598       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1604   1609       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1610   1612       {ECO:0000244|PDB:3PG7}.
FT   TURN       1615   1617       {ECO:0000244|PDB:2D4Q}.
FT   HELIX      1620   1631       {ECO:0000244|PDB:3PG7}.
FT   TURN       1632   1636       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1639   1644       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1650   1652       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1656   1661       {ECO:0000244|PDB:3PG7}.
FT   TURN       1662   1664       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1668   1672       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1674   1681       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1684   1692       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1694   1697       {ECO:0000244|PDB:3PG7}.
FT   TURN       1698   1702       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1706   1711       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1714   1717       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1721   1723       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1728   1732       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1738   1749       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1751   1757       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1759   1767       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1770   1772       {ECO:0000244|PDB:2D4Q}.
FT   STRAND     1775   1777       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1780   1784       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1785   1787       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1788   1795       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1798   1803       {ECO:0000244|PDB:3PG7}.
FT   STRAND     1810   1813       {ECO:0000244|PDB:3PG7}.
FT   HELIX      1817   1833       {ECO:0000244|PDB:3PG7}.
SQ   SEQUENCE   2839 AA;  319372 MW;  C079475139DBD51E CRC64;
     MAAHRPVEWV QAVVSRFDEQ LPIKTGQQNT HTKVSTEHNK ECLINISKYK FSLVISGLTT
     ILKNVNNMRI FGEAAEKNLY LSQLIILDTL EKCLAGQPKD TMRLDETMLV KQLLPEICHF
     LHTCREGNQH AAELRNSASG VLFSLSCNNF NAVFSRISTR LQELTVCSED NVDVHDIELL
     QYINVDCAKL KRLLKETAFK FKALKKVAQL AVINSLEKAF WNWVENYPDE FTKLYQIPQT
     DMAECAEKLF DLVDGFAEST KRKAAVWPLQ IILLILCPEI IQDISKDVVD ENNMNKKLFL
     DSLRKALAGH GGSRQLTESA AIACVKLCKA STYINWEDNS VIFLLVQSMV VDLKNLLFNP
     SKPFSRGSQP ADVDLMIDCL VSCFRISPHN NQHFKICLAQ NSPSTFHYVL VNSLHRIITN
     SALDWWPKID AVYCHSVELR NMFGETLHKA VQGCGAHPAI RMAPSLTFKE KVTSLKFKEK
     PTDLETRSYK YLLLSMVKLI HADPKLLLCN PRKQGPETQG STAELITGLV QLVPQSHMPE
     IAQEAMEALL VLHQLDSIDL WNPDAPVETF WEISSQMLFY ICKKLTSHQM LSSTEILKWL
     REILICRNKF LLKNKQADRS SCHFLLFYGV GCDIPSSGNT SQMSMDHEEL LRTPGASLRK
     GKGNSSMDSA AGCSGTPPIC RQAQTKLEVA LYMFLWNPDT EAVLVAMSCF RHLCEEADIR
     CGVDEVSVHN LLPNYNTFME FASVSNMMST GRAALQKRVM ALLRRIEHPT AGNTEAWEDT
     HAKWEQATKL ILNYPKAKME DGQAAESLHK TIVKRRMSHV SGGGSIDLSD TDSLQEWINM
     TGFLCALGGV CLQQRSNSGL ATYSPPMGPV SERKGSMISV MSSEGNADTP VSKFMDRLLS
     LMVCNHEKVG LQIRTNVKDL VGLELSPALY PMLFNKLKNT ISKFFDSQGQ VLLTDTNTQF
     VEQTIAIMKN LLDNHTEGSS EHLGQASIET MMLNLVRYVR VLGNMVHAIQ IKTKLCQLVE
     VMMARRDDLS FCQEMKFRNK MVEYLTDWVM GTSNQAADDD VKCLTRDLDQ ASMEAVVSLL
     AGLPLQPEEG DGVELMEAKS QLFLKYFTLF MNLLNDCSEV EDESAQTGGR KRGMSRRLAS
     LRHCTVLAMS NLLNANVDSG LMHSIGLGYH KDLQTRATFM EVLTKILQQG TEFDTLAETV
     LADRFERLVE LVTMMGDQGE LPIAMALANV VPCSQWDELA RVLVTLFDSR HLLYQLLWNM
     FSKEVELADS MQTLFRGNSL ASKIMTFCFK VYGATYLQKL LDPLLRIVIT SSDWQHVSFE
     VDPTRLEPSE SLEENQRNLL QMTEKFFHAI ISSSSEFPPQ LRSVCHCLYQ ATCHSLLNKA
     TVKEKKENKK SVVSQRFPQN SIGAVGSAMF LRFINPAIVS PYEAGILDKK PPPRIERGLK
     LMSKILQSIA NHVLFTKEEH MRPFNDFVKS NFDAARRFFL DIASDCPTSD AVNHSLSFIS
     DGNVLALHRL LWNNQEKIGQ YLSSNRDHKA VGRRPFDKMA TLLAYLGPPE HKPVADTHWS
     SLNLTSSKFE EFMTRHQVHE KEEFKALKTL SIFYQAGTSK AGNPIFYYVA RRFKTGQING
     DLLIYHVLLT LKPYYAKPYE IVVDLTHTGP SNRFKTDFLS KWFVVFPGFA YDNVSAVYIY
     NCNSWVREYT KYHERLLTGL KGSKRLVFID CPGKLAEHIE HEQQKLPAAT LALEEDLKVF
     HNALKLAHKD TKVSIKVGST AVQVTSAERT KVLGQSVFLN DIYYASEIEE ICLVDENQFT
     LTIANQGTPL TFMHQECEAI VQSIIHIRTR WELSQPDSIP QHTKIRPKDV PGTLLNIALL
     NLGSSDPSLR SAAYNLLCAL TCTFNLKIEG QLLETSGLCI PANNTLFIVS ISKTLAANEP
     HLTLEFLEEC ISGFSKSSIE LKHLCLEYMT PWLSNLVRFC KHNDDAKRQR VTAILDKLIT
     MTINEKQMYP SIQAKIWGSL GQITDLLDVV LDSFIKTSAT GGLGSIKAEV MADTAVALAS
     GNVKLVSSKV IGRMCKIIDK TCLSPTPTLE QHLMWDDIAI LARYMLMLSF NNSLDVAAHL
     PYLFHVVTFL VATGPLSLRA STHGLVINII HSLCTCSQLH FSEETKQVLR LSLTEFSLPK
     FYLLFGISKV KSAAVIAFRS SYRDRSFSPG SYERETFALT SLETVTEALL EIMEACMRDI
     PTCKWLDQWT ELAQRFAFQY NPSLQPRALV VFGCISKRVS HGQIKQIIRI LSKALESCLK
     GPDTYNSQVL IEATVIALTK LQPLLNKDSP LHKALFWVAV AVLQLDEVNL YSAGTALLEQ
     NLHTLDSLRI FNDKSPEEVF MAIRNPLEWH CKQMDHFVGL NFNSNFNFAL VGHLLKGYRH
     PSPAIVARTV RILHTLLTLV NKHRNCDKFE VNTQSVAYLA ALLTVSEEVR SRCSLKHRKS
     LLLTDISMEN VPMDTYPIHH GDPSYRTLKE TQPWSSPKGS EGYLAATYPT VGQTSPRARK
     SMSLDMGQPS QANTKKLLGT RKSFDHLISD TKAPKRQEME SGITTPPKMR RVAETDYEME
     TQRISSSQQH PHLRKVSVSE SNVLLDEEVL TDPKIQALLL TVLATLVKYT TDEFDQRILY
     EYLAEASVVF PKVFPVVHNL LDSKINTLLS LCQDPNLLNP IHGIVQSVVY HEESPPQYQT
     SYLQSFGFNG LWRFAGPFSK QTQIPDYAEL IVKFLDALID TYLPGIDEET SEESLLTPTS
     PYPPALQSQL SITANLNLSN SMTSLATSQH SPGIDKENVE LSPTTGHCNS GRTRHGSASQ
     VQKQRSAGSF KRNSIKKIV
//
ID   CSPG2_HUMAN             Reviewed;        3396 AA.
AC   P13611; P20754; Q13010; Q13189; Q15123; Q9UCL9; Q9UNW5;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 3.
DT   13-NOV-2019, entry version 228.
DE   RecName: Full=Versican core protein;
DE   AltName: Full=Chondroitin sulfate proteoglycan core protein 2;
DE            Short=Chondroitin sulfate proteoglycan 2;
DE   AltName: Full=Glial hyaluronate-binding protein;
DE            Short=GHAP;
DE   AltName: Full=Large fibroblast proteoglycan;
DE   AltName: Full=PG-M;
DE   Flags: Precursor;
GN   Name=VCAN; Synonyms=CSPG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM V1), AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=2583089; DOI=10.1002/j.1460-2075.1989.tb08447.x;
RA   Zimmermann D.R., Ruoslahti E.;
RT   "Multiple domains of the large fibroblast proteoglycan, versican.";
RL   EMBO J. 8:2975-2981(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM V2).
RC   TISSUE=Glial tumor;
RX   PubMed=7806529;
RA   Dours-Zimmermann M.T., Zimmermann D.R.;
RT   "A novel glycosaminoglycan attachment domain identified in two
RT   alternative splice variants of human versican.";
RL   J. Biol. Chem. 269:32992-32998(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM V0).
RX   PubMed=7528742;
RA   Naso M.F., Zimmermann D.R., Iozzo R.V.;
RT   "Characterization of the complete genomic structure of the human
RT   versican gene and functional analysis of its promoter.";
RL   J. Biol. Chem. 269:32999-33008(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM V3).
RC   TISSUE=Brain;
RX   PubMed=7876137; DOI=10.1074/jbc.270.8.3914;
RA   Zako M., Shinomura T., Ujita M., Ito K., Kimata K.;
RT   "Expression of PG-M(V3), an alternatively spliced form of PG-M without
RT   a chondroitin sulfate attachment in region in mouse and human
RT   tissues.";
RL   J. Biol. Chem. 270:3914-3918(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 208-1427; 2081-2372 AND 2897-3233
RP   (ISOFORM V1), AND DEVELOPMENTAL STAGE.
RX   PubMed=7921538; DOI=10.1016/0945-053x(94)90185-6;
RA   Yao L.Y., Moody C., Schoenherr E., Wight T.N., Sandell L.J.;
RT   "Identification of the proteoglycan versican in aorta and smooth
RT   muscle cells by DNA sequence analysis, in situ hybridization and
RT   immunohistochemistry.";
RL   Matrix Biol. 14:213-225(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-347.
RX   PubMed=1478664; DOI=10.1016/s0888-7543(05)80103-x;
RA   Iozzo R.V., Naso M.F., Cannizzaro L.A., Wasmuth J.J., McPherson J.D.;
RT   "Mapping of the versican proteoglycan gene (CSPG2) to the long arm of
RT   human chromosome 5 (5q12-5q14).";
RL   Genomics 14:845-851(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2709-3396.
RC   TISSUE=Lung fibroblast;
RX   PubMed=2820964;
RA   Krusius T., Gehlsen K.R., Ruoslahti E.;
RT   "A fibroblast chondroitin sulfate proteoglycan core protein contains
RT   lectin-like and growth factor-like sequences.";
RL   J. Biol. Chem. 262:13120-13125(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3333-3396 (ISOFORM VINT).
RC   TISSUE=Aortic smooth muscle;
RX   PubMed=10397680; DOI=10.1161/01.atv.19.7.1630;
RA   Lemire J.M., Braun K.R., Maurel P., Kaplan E.D., Schwartz S.M.,
RA   Wight T.N.;
RT   "Versican/PG-M isoforms in vascular smooth muscle cells.";
RL   Arterioscler. Thromb. Vasc. Biol. 19:1630-1639(1999).
RN   [9]
RP   PROTEIN SEQUENCE OF 21-37.
RX   PubMed=1429726;
RA   Perides G., Rahemtulla F., Lane W.S., Asher R.A., Bignami A.;
RT   "Isolation of a large aggregating proteoglycan from human brain.";
RL   J. Biol. Chem. 267:23883-23887(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 24-50; 80-119; 128-155; 167-218; 229-268 AND
RP   277-290.
RC   TISSUE=Brain;
RX   PubMed=2466833;
RA   Perides G., Lane W.S., Andrews D., Dahl D., Bignami A.;
RT   "Isolation and partial characterization of a glial hyaluronate-binding
RT   protein.";
RL   J. Biol. Chem. 264:5981-5987(1989).
RN   [11]
RP   PROTEIN SEQUENCE OF 171-210 AND 289-303, AND TISSUE SPECIFICITY.
RX   PubMed=2469524; DOI=10.1016/0361-9230(89)90129-9;
RA   Bignami A., Lane W.S., Andrews D., Dahl D.;
RT   "Structural similarity of hyaluronate binding proteins in brain and
RT   cartilage.";
RL   Brain Res. Bull. 22:67-70(1989).
RN   [12]
RP   TISSUE SPECIFICITY (ISOFORMS V0; V1; V2 AND V3).
RX   PubMed=8627343; DOI=10.1097/00005072-199605000-00005;
RA   Paulus W., Baur I., Dours-Zimmermann M.T., Zimmermann D.R.;
RT   "Differential expression of versican isoforms in brain tumors.";
RL   J. Neuropathol. Exp. Neurol. 55:528-533(1996).
RN   [13]
RP   INVOLVEMENT IN WGVRP.
RX   PubMed=16043844; DOI=10.1167/iovs.05-0057;
RA   Miyamoto T., Inoue H., Sakamoto Y., Kudo E., Naito T., Mikawa T.,
RA   Mikawa Y., Isashiki Y., Osabe D., Shinohara S., Shiota H., Itakura M.;
RT   "Identification of a novel splice site mutation of the CSPG2 gene in a
RT   Japanese family with Wagner syndrome.";
RL   Invest. Ophthalmol. Vis. Sci. 46:2726-2735(2005).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   INVOLVEMENT IN WGVRP, AND PATHOLOGICAL MECHANISM.
RX   PubMed=22739342; DOI=10.1038/ejhg.2012.137;
RA   Kloeckener-Gruissem B., Neidhardt J., Magyar I., Plauchu H.,
RA   Zech J.C., Morle L., Palmer-Smith S.M., Macdonald M.J., Nas V.,
RA   Fry A.E., Berger W.;
RT   "Novel VCAN mutations and evidence for unbalanced alternative splicing
RT   in the pathogenesis of Wagner syndrome.";
RL   Eur. J. Hum. Genet. 21:352-356(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2116 AND THR-2617, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   PHOSPHORYLATION AT SER-2116.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [18]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=29777959; DOI=10.1016/j.actbio.2018.05.023;
RA   Felemban M., Dorgau B., Hunt N.C., Hallam D., Zerti D., Bauer R.,
RA   Ding Y., Collin J., Steel D., Krasnogor N., Al-Aama J., Lindsay S.,
RA   Mellough C., Lako M.;
RT   "Extracellular matrix component expression in human pluripotent stem
RT   cell-derived retinal organoids recapitulates retinogenesis in vivo and
RT   reveals an important role for IMPG1 and CD44 in the development of
RT   photoreceptors and interphotoreceptor matrix.";
RL   Acta Biomater. 74:207-221(2018).
CC   -!- FUNCTION: May play a role in intercellular signaling and in
CC       connecting cells with the extracellular matrix. May take part in
CC       the regulation of cell motility, growth and differentiation. Binds
CC       hyaluronic acid.
CC   -!- SUBUNIT: Interacts with FBLN1. {ECO:0000250}.
CC   -!- INTERACTION:
CC       P14780:MMP9; NbExp=3; IntAct=EBI-8515977, EBI-1382326;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000305|PubMed:2583089}. Cell projection, cilium,
CC       photoreceptor outer segment {ECO:0000269|PubMed:29777959}.
CC       Secreted, extracellular space, extracellular matrix,
CC       interphotoreceptor matrix {ECO:0000269|PubMed:29777959}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=V0;
CC         IsoId=P13611-1; Sequence=Displayed;
CC       Name=V1;
CC         IsoId=P13611-2; Sequence=VSP_003082, VSP_003083;
CC       Name=V2;
CC         IsoId=P13611-3; Sequence=VSP_003084;
CC       Name=V3;
CC         IsoId=P13611-4; Sequence=VSP_003082, VSP_003085;
CC       Name=Vint;
CC         IsoId=P13611-5; Sequence=VSP_003086;
CC   -!- TISSUE SPECIFICITY: Expressed in the retina (at protein level)
CC       (PubMed:29777959). Cerebral white matter and plasma
CC       (PubMed:2469524). Isoform V0: Expressed in normal brain, gliomas,
CC       medulloblastomas, schwannomas, neurofibromas, and meningiomas
CC       (PubMed:8627343). Isoform V1: Expressed in normal brain, gliomas,
CC       medulloblastomas, schwannomas, neurofibromas, and meningiomas
CC       (PubMed:8627343). Isoform V2: Restricted to normal brain and
CC       gliomas (PubMed:8627343). Isoform V3: Found in all these tissues
CC       except medulloblastomas (PubMed:8627343).
CC       {ECO:0000269|PubMed:2469524, ECO:0000269|PubMed:29777959,
CC       ECO:0000269|PubMed:8627343}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in developing photoreceptors and
CC       the interphotoreceptor matrix between 12 and 17 weeks post
CC       conception (at protein level) (PubMed:29777959). Disappears in
CC       aorta after the cartilage development (PubMed:7921538).
CC       {ECO:0000269|PubMed:29777959, ECO:0000269|PubMed:7921538}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- DISEASE: Wagner vitreoretinopathy (WGVRP) [MIM:143200]: A rare
CC       vitreoretinopathy characterized by an optically empty vitreous
CC       cavity with fibrillary condensations and a preretinal avascular
CC       membrane. Other optical features include progressive chorioretinal
CC       atrophy, perivascular sheating, subcapsular cataract and myopia.
CC       {ECO:0000269|PubMed:16043844, ECO:0000269|PubMed:22739342}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. The pathological mechanism involves a
CC       quantitative imbalance of the normally occurring splice variants
CC       (PubMed:22739342). {ECO:0000269|PubMed:22739342}.
CC   -!- SIMILARITY: Belongs to the aggrecan/versican proteoglycan family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Versican;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_214";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/VCANID40173ch5q14.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; X15998; CAA34128.1; -; mRNA.
DR   EMBL; U16306; AAA65018.1; -; mRNA.
DR   EMBL; U26555; AAA67565.1; -; mRNA.
DR   EMBL; D32039; BAA06801.1; -; mRNA.
DR   EMBL; S52488; AAB24878.1; -; Genomic_DNA.
DR   EMBL; J02814; AAA36437.1; -; mRNA.
DR   EMBL; AF084545; AAD48545.1; -; mRNA.
DR   CCDS; CCDS4060.1; -. [P13611-1]
DR   CCDS; CCDS47242.1; -. [P13611-4]
DR   CCDS; CCDS54875.1; -. [P13611-3]
DR   CCDS; CCDS54876.1; -. [P13611-2]
DR   PIR; S06014; A60979.
DR   RefSeq; NP_001119808.1; NM_001126336.2. [P13611-4]
DR   RefSeq; NP_001157569.1; NM_001164097.1. [P13611-2]
DR   RefSeq; NP_001157570.1; NM_001164098.1. [P13611-3]
DR   RefSeq; NP_004376.2; NM_004385.4. [P13611-1]
DR   SMR; P13611; -.
DR   BioGrid; 107844; 21.
DR   IntAct; P13611; 10.
DR   MINT; P13611; -.
DR   STRING; 9606.ENSP00000265077; -.
DR   DrugBank; DB08818; Hyaluronic acid.
DR   CarbonylDB; P13611; -.
DR   GlyConnect; 1890; -.
DR   iPTMnet; P13611; -.
DR   PhosphoSitePlus; P13611; -.
DR   SwissPalm; P13611; -.
DR   BioMuta; VCAN; -.
DR   DMDM; 2506816; -.
DR   EPD; P13611; -.
DR   jPOST; P13611; -.
DR   MassIVE; P13611; -.
DR   MaxQB; P13611; -.
DR   PaxDb; P13611; -.
DR   PeptideAtlas; P13611; -.
DR   PRIDE; P13611; -.
DR   ProteomicsDB; 52938; -. [P13611-1]
DR   ProteomicsDB; 52939; -. [P13611-2]
DR   ProteomicsDB; 52940; -. [P13611-3]
DR   ProteomicsDB; 52941; -. [P13611-4]
DR   ProteomicsDB; 52942; -. [P13611-5]
DR   DNASU; 1462; -.
DR   Ensembl; ENST00000265077; ENSP00000265077; ENSG00000038427. [P13611-1]
DR   Ensembl; ENST00000342785; ENSP00000342768; ENSG00000038427. [P13611-3]
DR   Ensembl; ENST00000343200; ENSP00000340062; ENSG00000038427. [P13611-2]
DR   Ensembl; ENST00000502527; ENSP00000421362; ENSG00000038427. [P13611-4]
DR   GeneID; 1462; -.
DR   KEGG; hsa:1462; -.
DR   UCSC; uc003kii.4; human. [P13611-1]
DR   CTD; 1462; -.
DR   DisGeNET; 1462; -.
DR   GeneCards; VCAN; -.
DR   GeneReviews; VCAN; -.
DR   HGNC; HGNC:2464; VCAN.
DR   HPA; CAB008979; -.
DR   HPA; HPA004726; -.
DR   MalaCards; VCAN; -.
DR   MIM; 118661; gene.
DR   MIM; 143200; phenotype.
DR   neXtProt; NX_P13611; -.
DR   OpenTargets; ENSG00000038427; -.
DR   Orphanet; 898; Wagner disease.
DR   PharmGKB; PA162408788; -.
DR   eggNOG; ENOG410IFXS; Eukaryota.
DR   eggNOG; ENOG410ZPDG; LUCA.
DR   GeneTree; ENSGT00940000156102; -.
DR   InParanoid; P13611; -.
DR   KO; K06793; -.
DR   OMA; QGSTTFV; -.
DR   OrthoDB; 74642at2759; -.
DR   PhylomeDB; P13611; -.
DR   TreeFam; TF332134; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022870; Chondroitin sulfate biosynthesis.
DR   Reactome; R-HSA-2022923; Dermatan sulfate biosynthesis.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3595172; Defective CHST3 causes SEDCJD.
DR   Reactome; R-HSA-3595174; Defective CHST14 causes EDS, musculocontractural type.
DR   Reactome; R-HSA-3595177; Defective CHSY1 causes TPBS.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   SIGNOR; P13611; -.
DR   ChiTaRS; VCAN; human.
DR   GeneWiki; Versican; -.
DR   GenomeRNAi; 1462; -.
DR   Pharos; P13611; -.
DR   PMAP-CutDB; P13611; -.
DR   PRO; PR:P13611; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000038427; Expressed in 242 organ(s), highest expression level in endometrium.
DR   ExpressionAtlas; P13611; baseline and differential.
DR   Genevisible; P13611; HS.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031012; C:extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; HDA:BHF-UCL.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0033165; C:interphotoreceptor matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0001750; C:photoreceptor outer segment; IEA:UniProtKB-SubCell.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0030021; F:extracellular matrix structural constituent conferring compression resistance; ISS:BHF-UCL.
DR   GO; GO:0005539; F:glycosaminoglycan binding; TAS:ProtInc.
DR   GO; GO:0005540; F:hyaluronic acid binding; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0008037; P:cell recognition; TAS:ProtInc.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0030206; P:chondroitin sulfate biosynthetic process; TAS:Reactome.
DR   GO; GO:0030207; P:chondroitin sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0030208; P:dermatan sulfate biosynthetic process; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0008347; P:glial cell migration; IDA:BHF-UCL.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0001649; P:osteoblast differentiation; HDA:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0001501; P:skeletal system development; IBA:GO_Central.
DR   CDD; cd00033; CCP; 1.
DR   CDD; cd03588; CLECT_CSPGs; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.100.10; -; 3.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR033987; CSPG_CTLD.
DR   InterPro; IPR016187; CTDL_fold.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR000538; Link_dom.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   Pfam; PF00008; EGF; 2.
DR   Pfam; PF00059; Lectin_C; 1.
DR   Pfam; PF00084; Sushi; 1.
DR   Pfam; PF07686; V-set; 1.
DR   Pfam; PF00193; Xlink; 2.
DR   PRINTS; PR01265; LINKMODULE.
DR   SMART; SM00032; CCP; 1.
DR   SMART; SM00034; CLECT; 1.
DR   SMART; SM00181; EGF; 2.
DR   SMART; SM00179; EGF_CA; 2.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00445; LINK; 2.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF56436; SSF56436; 3.
DR   SUPFAM; SSF57535; SSF57535; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 1.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 2.
DR   PROSITE; PS01187; EGF_CA; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS01241; LINK_1; 2.
DR   PROSITE; PS50963; LINK_2; 2.
DR   PROSITE; PS50923; SUSHI; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cataract; Cell projection;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   EGF-like domain; Extracellular matrix; Glycoprotein; Hyaluronic acid;
KW   Immunoglobulin domain; Lectin; Phosphoprotein; Polymorphism;
KW   Proteoglycan; Reference proteome; Repeat; Secreted; Signal; Sushi.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:1429726}.
FT   CHAIN        21   3396       Versican core protein.
FT                                /FTId=PRO_0000017522.
FT   DOMAIN       21    146       Ig-like V-type.
FT   DOMAIN      150    245       Link 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00323}.
FT   DOMAIN      251    347       Link 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00323}.
FT   DOMAIN     3089   3125       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     3127   3163       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     3176   3290       C-type lectin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00040}.
FT   DOMAIN     3294   3354       Sushi. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00302}.
FT   REGION      348   1335       GAG-alpha (glucosaminoglycan attachment
FT                                domain).
FT   REGION     1336   3089       GAG-beta.
FT   MOD_RES    2116   2116       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES    2608   2608       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62059}.
FT   MOD_RES    2617   2617       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     57     57       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    615    615       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    782    782       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    809    809       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1332   1332       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1398   1398       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1442   1442       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1468   1468       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1663   1663       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1898   1898       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2179   2179       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2272   2272       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2280   2280       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2360   2360       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2385   2385       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2392   2392       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2496   2496       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2628   2628       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   2934   2934       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   3067   3067       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   3369   3369       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   3379   3379       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     44    130       {ECO:0000250}.
FT   DISULFID    172    243       {ECO:0000250}.
FT   DISULFID    196    217       {ECO:0000250}.
FT   DISULFID    270    345       {ECO:0000250}.
FT   DISULFID    294    315       {ECO:0000250}.
FT   DISULFID   3093   3104       {ECO:0000250}.
FT   DISULFID   3098   3113       {ECO:0000250}.
FT   DISULFID   3115   3124       {ECO:0000250}.
FT   DISULFID   3131   3142       {ECO:0000250}.
FT   DISULFID   3136   3151       {ECO:0000250}.
FT   DISULFID   3153   3162       {ECO:0000250}.
FT   DISULFID   3169   3180       {ECO:0000250}.
FT   DISULFID   3197   3289       {ECO:0000250}.
FT   DISULFID   3265   3281       {ECO:0000250}.
FT   DISULFID   3296   3339       {ECO:0000250}.
FT   DISULFID   3325   3352       {ECO:0000250}.
FT   VAR_SEQ     348    348       P -> R (in isoform V1 and isoform V3).
FT                                {ECO:0000303|PubMed:2583089,
FT                                ECO:0000303|PubMed:7876137,
FT                                ECO:0000303|PubMed:7921538}.
FT                                /FTId=VSP_003082.
FT   VAR_SEQ     349   3089       Missing (in isoform V3).
FT                                {ECO:0000303|PubMed:7876137}.
FT                                /FTId=VSP_003085.
FT   VAR_SEQ     349   1335       Missing (in isoform V1).
FT                                {ECO:0000303|PubMed:2583089,
FT                                ECO:0000303|PubMed:7921538}.
FT                                /FTId=VSP_003083.
FT   VAR_SEQ    1336   3089       Missing (in isoform V2).
FT                                {ECO:0000303|PubMed:7806529}.
FT                                /FTId=VSP_003084.
FT   VAR_SEQ    3355   3396       PSAYQRTYSMKYFKNSSSAKDNSINTSKHDHRWSRRWQESR
FT                                R -> RKWSFRKNGLPCYNNY (in isoform Vint).
FT                                {ECO:0000303|PubMed:10397680}.
FT                                /FTId=VSP_003086.
FT   VARIANT     300    300       S -> L (in dbSNP:rs2652098).
FT                                /FTId=VAR_021958.
FT   VARIANT     428    428       G -> D (in dbSNP:rs2287926).
FT                                /FTId=VAR_020214.
FT   VARIANT    1516   1516       K -> R (in dbSNP:rs309559).
FT                                /FTId=VAR_021959.
FT   VARIANT    1826   1826       R -> H (in dbSNP:rs188703).
FT                                /FTId=VAR_031632.
FT   VARIANT    2301   2301       F -> Y (in dbSNP:rs160278).
FT                                /FTId=VAR_020215.
FT   VARIANT    2315   2315       V -> L (in dbSNP:rs3734094).
FT                                /FTId=VAR_020216.
FT   VARIANT    2937   2937       D -> Y (in dbSNP:rs160277).
FT                                /FTId=VAR_021960.
FT   VARIANT    3011   3011       N -> K (in dbSNP:rs16900532).
FT                                /FTId=VAR_031633.
FT   CONFLICT     88     88       N -> D (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    260    260       K -> I (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    274    274       D -> A (in Ref. 4; BAA06801).
FT                                {ECO:0000305}.
FT   CONFLICT    284    284       Q -> G (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   2709   2713       IKAEA -> EFREV (in Ref. 7; AAA36437).
FT                                {ECO:0000305}.
SQ   SEQUENCE   3396 AA;  372820 MW;  D174A1BBB8304FEC CRC64;
     MFINIKSILW MCSTLIVTHA LHKVKVGKSP PVRGSLSGKV SLPCHFSTMP TLPPSYNTSE
     FLRIKWSKIE VDKNGKDLKE TTVLVAQNGN IKIGQDYKGR VSVPTHPEAV GDASLTVVKL
     LASDAGLYRC DVMYGIEDTQ DTVSLTVDGV VFHYRAATSR YTLNFEAAQK ACLDVGAVIA
     TPEQLFAAYE DGFEQCDAGW LADQTVRYPI RAPRVGCYGD KMGKAGVRTY GFRSPQETYD
     VYCYVDHLDG DVFHLTVPSK FTFEEAAKEC ENQDARLATV GELQAAWRNG FDQCDYGWLS
     DASVRHPVTV ARAQCGGGLL GVRTLYRFEN QTGFPPPDSR FDAYCFKPKE ATTIDLSILA
     ETASPSLSKE PQMVSDRTTP IIPLVDELPV IPTEFPPVGN IVSFEQKATV QPQAITDSLA
     TKLPTPTGST KKPWDMDDYS PSASGPLGKL DISEIKEEVL QSTTGVSHYA TDSWDGVVED
     KQTQESVTQI EQIEVGPLVT SMEILKHIPS KEFPVTETPL VTARMILESK TEKKMVSTVS
     ELVTTGHYGF TLGEEDDEDR TLTVGSDEST LIFDQIPEVI TVSKTSEDTI HTHLEDLESV
     SASTTVSPLI MPDNNGSSMD DWEERQTSGR ITEEFLGKYL STTPFPSQHR TEIELFPYSG
     DKILVEGIST VIYPSLQTEM THRRERTETL IPEMRTDTYT DEIQEEITKS PFMGKTEEEV
     FSGMKLSTSL SEPIHVTESS VEMTKSFDFP TLITKLSAEP TEVRDMEEDF TATPGTTKYD
     ENITTVLLAH GTLSVEAATV SKWSWDEDNT TSKPLESTEP SASSKLPPAL LTTVGMNGKD
     KDIPSFTEDG ADEFTLIPDS TQKQLEEVTD EDIAAHGKFT IRFQPTTSTG IAEKSTLRDS
     TTEEKVPPIT STEGQVYATM EGSALGEVED VDLSKPVSTV PQFAHTSEVE GLAFVSYSST
     QEPTTYVDSS HTIPLSVIPK TDWGVLVPSV PSEDEVLGEP SQDILVIDQT RLEATISPET
     MRTTKITEGT TQEEFPWKEQ TAEKPVPALS STAWTPKEAV TPLDEQEGDG SAYTVSEDEL
     LTGSERVPVL ETTPVGKIDH SVSYPPGAVT EHKVKTDEVV TLTPRIGPKV SLSPGPEQKY
     ETEGSSTTGF TSSLSPFSTH ITQLMEETTT EKTSLEDIDL GSGLFEKPKA TELIEFSTIK
     VTVPSDITTA FSSVDRLHTT SAFKPSSAIT KKPPLIDREP GEETTSDMVI IGESTSHVPP
     TTLEDIVAKE TETDIDREYF TTSSPPATQP TRPPTVEDKE AFGPQALSTP QPPASTKFHP
     DINVYIIEVR ENKTGRMSDL SVIGHPIDSE SKEDEPCSEE TDPVHDLMAE ILPEFPDIIE
     IDLYHSEENE EEEEECANAT DVTTTPSVQY INGKHLVTTV PKDPEAAEAR RGQFESVAPS
     QNFSDSSESD THPFVIAKTE LSTAVQPNES TETTESLEVT WKPETYPETS EHFSGGEPDV
     FPTVPFHEEF ESGTAKKGAE SVTERDTEVG HQAHEHTEPV SLFPEESSGE IAIDQESQKI
     AFARATEVTF GEEVEKSTSV TYTPTIVPSS ASAYVSEEEA VTLIGNPWPD DLLSTKESWV
     EATPRQVVEL SGSSSIPITE GSGEAEEDED TMFTMVTDLS QRNTTDTLIT LDTSRIITES
     FFEVPATTIY PVSEQPSAKV VPTKFVSETD TSEWISSTTV EEKKRKEEEG TTGTASTFEV
     YSSTQRSDQL ILPFELESPN VATSSDSGTR KSFMSLTTPT QSEREMTDST PVFTETNTLE
     NLGAQTTEHS SIHQPGVQEG LTTLPRSPAS VFMEQGSGEA AADPETTTVS SFSLNVEYAI
     QAEKEVAGTL SPHVETTFST EPTGLVLSTV MDRVVAENIT QTSREIVISE RLGEPNYGAE
     IRGFSTGFPL EEDFSGDFRE YSTVSHPIAK EETVMMEGSG DAAFRDTQTS PSTVPTSVHI
     SHISDSEGPS STMVSTSAFP WEEFTSSAEG SGEQLVTVSS SVVPVLPSAV QKFSGTASSI
     IDEGLGEVGT VNEIDRRSTI LPTAEVEGTK APVEKEEVKV SGTVSTNFPQ TIEPAKLWSR
     QEVNPVRQEI ESETTSEEQI QEEKSFESPQ NSPATEQTIF DSQTFTETEL KTTDYSVLTT
     KKTYSDDKEM KEEDTSLVNM STPDPDANGL ESYTTLPEAT EKSHFFLATA LVTESIPAEH
     VVTDSPIKKE ESTKHFPKGM RPTIQESDTE LLFSGLGSGE EVLPTLPTES VNFTEVEQIN
     NTLYPHTSQV ESTSSDKIED FNRMENVAKE VGPLVSQTDI FEGSGSVTST TLIEILSDTG
     AEGPTVAPLP FSTDIGHPQN QTVRWAEEIQ TSRPQTITEQ DSNKNSSTAE INETTTSSTD
     FLARAYGFEM AKEFVTSAPK PSDLYYEPSG EGSGEVDIVD SFHTSATTQA TRQESSTTFV
     SDGSLEKHPE VPSAKAVTAD GFPTVSVMLP LHSEQNKSSP DPTSTLSNTV SYERSTDGSF
     QDRFREFEDS TLKPNRKKPT ENIIIDLDKE DKDLILTITE STILEILPEL TSDKNTIIDI
     DHTKPVYEDI LGMQTDIDTE VPSEPHDSND ESNDDSTQVQ EIYEAAVNLS LTEETFEGSA
     DVLASYTQAT HDESMTYEDR SQLDHMGFHF TTGIPAPSTE TELDVLLPTA TSLPIPRKSA
     TVIPEIEGIK AEAKALDDMF ESSTLSDGQA IADQSEIIPT LGQFERTQEE YEDKKHAGPS
     FQPEFSSGAE EALVDHTPYL SIATTHLMDQ SVTEVPDVME GSNPPYYTDT TLAVSTFAKL
     SSQTPSSPLT IYSGSEASGH TEIPQPSALP GIDVGSSVMS PQDSFKEIHV NIEATFKPSS
     EEYLHITEPP SLSPDTKLEP SEDDGKPELL EEMEASPTEL IAVEGTEILQ DFQNKTDGQV
     SGEAIKMFPT IKTPEAGTVI TTADEIELEG ATQWPHSTSA SATYGVEAGV VPWLSPQTSE
     RPTLSSSPEI NPETQAALIR GQDSTIAASE QQVAARILDS NDQATVNPVE FNTEVATPPF
     SLLETSNETD FLIGINEESV EGTAIYLPGP DRCKMNPCLN GGTCYPTETS YVCTCVPGYS
     GDQCELDFDE CHSNPCRNGA TCVDGFNTFR CLCLPSYVGA LCEQDTETCD YGWHKFQGQC
     YKYFAHRRTW DAAERECRLQ GAHLTSILSH EEQMFVNRVG HDYQWIGLND KMFEHDFRWT
     DGSTLQYENW RPNQPDSFFS AGEDCVVIIW HENGQWNDVP CNYHLTYTCK KGTVACGQPP
     VVENAKTFGK MKPRYEINSL IRYHCKDGFI QRHLPTIRCL GNGRWAIPKI TCMNPSAYQR
     TYSMKYFKNS SSAKDNSINT SKHDHRWSRR WQESRR
//
ID   PMP22_RAT               Reviewed;         160 AA.
AC   P25094;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   16-OCT-2019, entry version 135.
DE   RecName: Full=Peripheral myelin protein 22;
DE            Short=PMP-22;
DE   AltName: Full=Protein CD25;
DE   AltName: Full=SR13 myelin protein;
DE   AltName: Full=Schwann cell membrane glycoprotein;
DE            Short=SAG;
GN   Name=Pmp22; Synonyms=Cd25, Pmp-22;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Sciatic nerve;
RX   PubMed=1935894; DOI=10.1002/j.1460-2075.1991.tb04933.x;
RA   Spreyer P., Kuhn G., Hanemann C.O., Gillen C., Schaal H., Kuhn R.,
RA   Lemke G., Mueller H.W.;
RT   "Axon-regulated expression of a Schwann cell transcript that is
RT   homologous to a 'growth arrest-specific' gene.";
RL   EMBO J. 10:3661-3668(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Sciatic nerve;
RX   PubMed=1714591; DOI=10.1073/pnas.88.16.7195;
RA   Welcher A.A., Suter U., de Leon M., Snipes G.J., Shooter E.M.;
RT   "A myelin protein is encoded by the homologue of a growth arrest-
RT   specific gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7195-7199(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1287719;
RA   Welcher A.A., de Leon M., Suter U., Snipes G.J., Meakin S.O.,
RA   Shooter E.M.;
RT   "Isolation of transcriptionally regulated sequences associated with
RT   neuronal and non-neuronal cell interactions.";
RL   Prog. Brain Res. 94:163-176(1992).
RN   [4]
RP   PROTEIN SEQUENCE OF 1-30, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=1376775; DOI=10.1523/jneurosci.12-06-02177.1992;
RA   Dieperink M.E., O'Neill A., Magnoni G., Wollmann R.L.,
RA   Heinrikson R.L., Zucher-Neely H.A., Stefansson K.;
RT   "SAG: a Schwann cell membrane glycoprotein.";
RL   J. Neurosci. 12:2177-2185(1992).
CC   -!- FUNCTION: Might be involved in growth regulation, and in
CC       myelinization in the peripheral nervous system.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Found exclusively in the peripheral nervous
CC       system. Present in both myelinating and nonmyelinating Schwann
CC       cells. Found in the tumors of Schwann cell lineage where axons are
CC       present (neurofibromas) but not where axons are absent
CC       (schwannomas). {ECO:0000269|PubMed:1376775}.
CC   -!- DEVELOPMENTAL STAGE: Levels increase between embryonic day 21
CC       (E21) and postnatal day 1 (P1) and then gradually increase up to
CC       P15. There is a slight increase between P15 and adulthood.
CC       {ECO:0000269|PubMed:1376775}.
CC   -!- INDUCTION: Strongly down-regulated in the initial phase after
CC       sciatic nerve injury.
CC   -!- SIMILARITY: Belongs to the PMP-22/EMP/MP20 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; X62431; CAA44297.1; -; mRNA.
DR   EMBL; M69139; AAA73063.1; -; mRNA.
DR   EMBL; S55427; AAB25374.1; -; mRNA.
DR   PIR; A41144; A41144.
DR   RefSeq; NP_058733.1; NM_017037.1.
DR   RefSeq; XP_006246646.1; XM_006246584.3.
DR   SMR; P25094; -.
DR   STRING; 10116.ENSRNOP00000051201; -.
DR   ChEMBL; CHEMBL2007624; -.
DR   PaxDb; P25094; -.
DR   PRIDE; P25094; -.
DR   Ensembl; ENSRNOT00000041606; ENSRNOP00000051201; ENSRNOG00000003338.
DR   Ensembl; ENSRNOT00000081415; ENSRNOP00000069909; ENSRNOG00000003338.
DR   GeneID; 24660; -.
DR   KEGG; rno:24660; -.
DR   UCSC; RGD:3359; rat.
DR   CTD; 5376; -.
DR   RGD; 3359; Pmp22.
DR   eggNOG; ENOG410IWVJ; Eukaryota.
DR   eggNOG; ENOG4111SX3; LUCA.
DR   GeneTree; ENSGT00950000182696; -.
DR   HOGENOM; HOG000059542; -.
DR   InParanoid; P25094; -.
DR   KO; K19289; -.
DR   OMA; EYSYGFA; -.
DR   OrthoDB; 1513895at2759; -.
DR   PhylomeDB; P25094; -.
DR   TreeFam; TF330414; -.
DR   PRO; PR:P25094; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000003338; Expressed in 9 organ(s), highest expression level in lung.
DR   Genevisible; P25094; RN.
DR   GO; GO:0005923; C:bicellular tight junction; IDA:RGD.
DR   GO; GO:0043218; C:compact myelin; IDA:RGD.
DR   GO; GO:0016021; C:integral component of membrane; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0032060; P:bleb assembly; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:UniProtKB-KW.
DR   GO; GO:0008219; P:cell death; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IDA:RGD.
DR   GO; GO:0032288; P:myelin assembly; IBA:GO_Central.
DR   GO; GO:0042552; P:myelination; IDA:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IDA:BHF-UCL.
DR   GO; GO:0007422; P:peripheral nervous system development; IC:BHF-UCL.
DR   InterPro; IPR003936; PMP22.
DR   InterPro; IPR004031; PMP22/EMP/MP20/Claudin.
DR   InterPro; IPR004032; PMP22_EMP_MP20.
DR   PANTHER; PTHR10671:SF7; PTHR10671:SF7; 1.
DR   Pfam; PF00822; PMP22_Claudin; 1.
DR   PRINTS; PR01453; EPMEMFAMILY.
DR   PRINTS; PR01458; PMYELIN22.
DR   PROSITE; PS01221; PMP22_1; 1.
DR   PROSITE; PS01222; PMP22_2; 1.
PE   1: Evidence at protein level;
KW   Cell cycle; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Glycoprotein; Growth arrest; Membrane;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN         1    160       Peripheral myelin protein 22.
FT                                /FTId=PRO_0000164652.
FT   TOPO_DOM      1      1       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      2     31       Helical. {ECO:0000250}.
FT   TOPO_DOM     32     64       Extracellular. {ECO:0000255}.
FT   TRANSMEM     65     91       Helical. {ECO:0000250}.
FT   TOPO_DOM     92     95       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     96    119       Helical. {ECO:0000250}.
FT   TOPO_DOM    120    133       Extracellular. {ECO:0000255}.
FT   TRANSMEM    134    156       Helical. {ECO:0000250}.
FT   TOPO_DOM    157    160       Cytoplasmic. {ECO:0000255}.
FT   CARBOHYD     41     41       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CONFLICT     22     22       S -> K (in Ref. 4; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     30     30       V -> E (in Ref. 1; CAA44297).
FT                                {ECO:0000305}.
SQ   SEQUENCE   160 AA;  17946 MW;  8DB9B2F2CF6D4903 CRC64;
     MLLLLLGILF LHIAVLVLLF VSTIVSQWLV GNGHRTDLWQ NCTTSALGAV QHCYSSSVSE
     WLQSVQATMI LSVIFSVLSL FLFFCQLFTL TKGGRFYITG VFQILAGLCV MSAAAIYTVR
     HSEWHVNNDY SYGFAYILAW VAFPLALLSG IIYVILRKRE
//
ID   SPRE1_HUMAN             Reviewed;         444 AA.
AC   Q7Z699; B2RPJ8; Q05D53; Q8N256;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   04-JAN-2005, sequence version 2.
DT   13-NOV-2019, entry version 148.
DE   RecName: Full=Sprouty-related, EVH1 domain-containing protein 1;
DE            Short=Spred-1;
DE            Short=hSpred1;
GN   Name=SPRED1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH SPRED2.
RC   TISSUE=Glioblastoma;
RX   PubMed=15683364; DOI=10.1042/bj20041284;
RA   King J.A.J., Straffon A.F.L., D'Abaco G.M., Poon C.L.C., I S.T.T.,
RA   Smith C.M., Buchert M., Corcoran N.M., Hall N.E., Callus B.A.,
RA   Sarcevic B., Martin D., Lock P., Hovens C.M.;
RT   "Distinct requirements for the Sprouty domain for functional activity
RT   of Spred proteins.";
RL   Biochem. J. 388:445-454(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=15580519; DOI=10.1007/s00418-004-0725-6;
RA   Engelhardt C.M., Bundschu K., Messerschmitt M., Renne T., Walter U.,
RA   Reinhard M., Schuh K.;
RT   "Expression and subcellular localization of Spred proteins in mouse
RT   and human tissues.";
RL   Histochem. Cell Biol. 122:527-538(2004).
RN   [6]
RP   INTERACTION WITH CAV1, AND SUBCELLULAR LOCATION.
RX   PubMed=16115197; DOI=10.1111/j.1365-2443.2005.00886.x;
RA   Nonami A., Taketomi T., Kimura A., Saeki K., Takaki H., Sanada T.,
RA   Taniguchi K., Harada M., Kato R., Yoshimura A.;
RT   "The Sprouty-related protein, Spred-1, localizes in a lipid
RT   raft/caveola and inhibits ERK activation in collaboration with
RT   caveolin-1.";
RL   Genes Cells 10:887-895(2005).
RN   [7]
RP   INVOLVEMENT IN LGSS.
RX   PubMed=17704776; DOI=10.1038/ng2113;
RA   Brems H., Chmara M., Sahbatou M., Denayer E., Taniguchi K., Kato R.,
RA   Somers R., Messiaen L., De Schepper S., Fryns J.-P., Cools J.,
RA   Marynen P., Thomas G., Yoshimura A., Legius E.;
RT   "Germline loss-of-function mutations in SPRED1 cause a
RT   neurofibromatosis 1-like phenotype.";
RL   Nat. Genet. 39:1120-1126(2007).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-238 AND SER-308, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT LYS-224, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [11]
RP   VARIANT LGSS ASP-44.
RX   PubMed=19443465; DOI=10.1136/jmg.2008.065474;
RA   Spurlock G., Bennett E., Chuzhanova N., Thomas N., Jim H.P., Side L.,
RA   Davies S., Haan E., Kerr B., Huson S.M., Upadhyaya M.;
RT   "SPRED1 mutations (Legius syndrome): another clinically useful
RT   genotype for dissecting the neurofibromatosis type 1 phenotype.";
RL   J. Med. Genet. 46:431-437(2009).
RN   [12]
RP   VARIANT LGSS ASP-44.
RX   PubMed=20108422;
RA   Jim H.P., Upadhyaya M.;
RT   "Novel human pathological mutations. Gene symbol: SPRED1. Disease:
RT   Legius syndrome.";
RL   Hum. Genet. 127:112-112(2010).
RN   [13]
RP   VARIANT LGSS CYS-31.
RX   PubMed=21089071; DOI=10.1002/humu.21404;
RA   Denayer E., Chmara M., Brems H., Kievit A.M., van Bever Y.,
RA   Van den Ouweland A.M., Van Minkelen R., de Goede-Bolder A.,
RA   Oostenbrink R., Lakeman P., Beert E., Ishizaki T., Mori T.,
RA   Keymolen K., Van den Ende J., Mangold E., Peltonen S., Brice G.,
RA   Rankin J., Van Spaendonck-Zwarts K.Y., Yoshimura A., Legius E.;
RT   "Legius syndrome in fourteen families.";
RL   Hum. Mutat. 32:E1985-E1998(2011).
CC   -!- FUNCTION: Tyrosine kinase substrate that inhibits growth-factor-
CC       mediated activation of MAP kinase. Negatively regulates
CC       hematopoiesis of bone marrow (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with Ras. Interacts with TAOK2 and TESK1 (By
CC       similarity). Homodimer and heterodimer. Interacts with CAV1. Able
CC       to interact with SPRED2 to form heterodimers. {ECO:0000250,
CC       ECO:0000269|PubMed:15683364, ECO:0000269|PubMed:16115197}.
CC   -!- INTERACTION:
CC       P61601:NCALD; NbExp=4; IntAct=EBI-5235340, EBI-749635;
CC       P21359:NF1; NbExp=6; IntAct=EBI-5235340, EBI-1172917;
CC       Q8WWB5:PIH1D2; NbExp=4; IntAct=EBI-5235340, EBI-10232538;
CC       P62136:PPP1CA; NbExp=4; IntAct=EBI-5235340, EBI-357253;
CC       Q8IUH5:ZDHHC17; NbExp=3; IntAct=EBI-5235340, EBI-524753;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16115197};
CC       Peripheral membrane protein {ECO:0000269|PubMed:16115197}.
CC       Membrane, caveola {ECO:0000269|PubMed:16115197}; Peripheral
CC       membrane protein {ECO:0000269|PubMed:16115197}. Nucleus
CC       {ECO:0000269|PubMed:16115197}. Note=Localized in cholesterol-rich
CC       membrane raft/caveola fractions.
CC   -!- TISSUE SPECIFICITY: Weakly expressed in embryonic cell line
CC       HEK293. {ECO:0000269|PubMed:15580519}.
CC   -!- PTM: Phosphorylated on tyrosine. {ECO:0000250}.
CC   -!- DISEASE: Legius syndrome (LGSS) [MIM:611431]: An autosomal
CC       dominant syndrome characterized mainly by cafe-au-lait macules
CC       without neurofibromas or other tumor manifestations of
CC       neurofibromatosis type 1, axillary freckling, and macrocephaly.
CC       Additional clinical manifestations include Noonan-like facial
CC       dysmorphism, lipomas, learning disabilities, and features of
CC       attention-deficit hyperactivity disorder.
CC       {ECO:0000269|PubMed:17704776, ECO:0000269|PubMed:19443465,
CC       ECO:0000269|PubMed:20108422, ECO:0000269|PubMed:21089071}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH18015.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AY299089; AAP59414.1; -; mRNA.
DR   EMBL; AK091222; BAC03614.1; -; mRNA.
DR   EMBL; CH471125; EAW92368.1; -; Genomic_DNA.
DR   EMBL; BC018015; AAH18015.1; ALT_SEQ; mRNA.
DR   EMBL; BC137480; AAI37481.1; -; mRNA.
DR   EMBL; BC137481; AAI37482.1; -; mRNA.
DR   CCDS; CCDS32193.1; -.
DR   RefSeq; NP_689807.1; NM_152594.2.
DR   PDB; 3SYX; X-ray; 2.45 A; A=13-131.
DR   PDBsum; 3SYX; -.
DR   SMR; Q7Z699; -.
DR   BioGrid; 127800; 18.
DR   IntAct; Q7Z699; 40.
DR   MINT; Q7Z699; -.
DR   STRING; 9606.ENSP00000299084; -.
DR   iPTMnet; Q7Z699; -.
DR   PhosphoSitePlus; Q7Z699; -.
DR   SwissPalm; Q7Z699; -.
DR   BioMuta; SPRED1; -.
DR   DMDM; 57013078; -.
DR   EPD; Q7Z699; -.
DR   jPOST; Q7Z699; -.
DR   MassIVE; Q7Z699; -.
DR   MaxQB; Q7Z699; -.
DR   PaxDb; Q7Z699; -.
DR   PeptideAtlas; Q7Z699; -.
DR   PRIDE; Q7Z699; -.
DR   ProteomicsDB; 69386; -.
DR   Ensembl; ENST00000299084; ENSP00000299084; ENSG00000166068.
DR   GeneID; 161742; -.
DR   KEGG; hsa:161742; -.
DR   UCSC; uc001zka.5; human.
DR   CTD; 161742; -.
DR   DisGeNET; 161742; -.
DR   GeneCards; SPRED1; -.
DR   GeneReviews; SPRED1; -.
DR   HGNC; HGNC:20249; SPRED1.
DR   HPA; HPA042193; -.
DR   HPA; HPA061805; -.
DR   MalaCards; SPRED1; -.
DR   MIM; 609291; gene.
DR   MIM; 611431; phenotype.
DR   neXtProt; NX_Q7Z699; -.
DR   OpenTargets; ENSG00000166068; -.
DR   Orphanet; 137605; Legius syndrome.
DR   PharmGKB; PA134897382; -.
DR   eggNOG; ENOG410IQ20; Eukaryota.
DR   eggNOG; ENOG4112CZ7; LUCA.
DR   GeneTree; ENSGT00940000159180; -.
DR   HOGENOM; HOG000220886; -.
DR   InParanoid; Q7Z699; -.
DR   KO; K04703; -.
DR   OMA; YLYPCGD; -.
DR   OrthoDB; 759156at2759; -.
DR   PhylomeDB; Q7Z699; -.
DR   TreeFam; TF321411; -.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   Reactome; R-HSA-5658623; FGFRL1 modulation of FGFR1 signaling.
DR   ChiTaRS; SPRED1; human.
DR   GeneWiki; SPRED1; -.
DR   GenomeRNAi; 161742; -.
DR   Pharos; Q7Z699; -.
DR   PRO; PR:Q7Z699; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000166068; Expressed in 203 organ(s), highest expression level in intestine.
DR   ExpressionAtlas; Q7Z699; baseline and differential.
DR   Genevisible; Q7Z699; HS.
DR   GO; GO:0005901; C:caveola; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:ARUK-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0019902; F:phosphatase binding; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; ISS:BHF-UCL.
DR   GO; GO:0005173; F:stem cell factor receptor binding; ISS:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000188; P:inactivation of MAPK activity; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:BHF-UCL.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0010923; P:negative regulation of phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:ARUK-UCL.
DR   GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; ISS:BHF-UCL.
DR   GO; GO:0043408; P:regulation of MAPK cascade; TAS:ARUK-UCL.
DR   GO; GO:0090311; P:regulation of protein deacetylation; ISS:BHF-UCL.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; IMP:BHF-UCL.
DR   CDD; cd10574; EVH1_SPRED-like; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR023337; KBD.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR041937; SPRE_EVH1.
DR   InterPro; IPR007875; Sprouty.
DR   InterPro; IPR000697; WH1/EVH1_dom.
DR   Pfam; PF05210; Sprouty; 1.
DR   Pfam; PF00568; WH1; 1.
DR   SMART; SM00461; WH1; 1.
DR   PROSITE; PS51488; KBD; 1.
DR   PROSITE; PS51227; SPR; 1.
DR   PROSITE; PS50229; WH1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Complete proteome;
KW   Disease mutation; Membrane; Methylation; Nucleus; Phosphoprotein;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    444       Sprouty-related, EVH1 domain-containing
FT                                protein 1.
FT                                /FTId=PRO_0000076907.
FT   DOMAIN        6    123       WH1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00410}.
FT   DOMAIN      233    285       KBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00821}.
FT   DOMAIN      334    442       SPR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00572}.
FT   COMPBIAS    147    150       Poly-Ser.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     224    224       N6-methyllysine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     238    238       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     308    308       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      31     31       W -> C (in LGSS).
FT                                {ECO:0000269|PubMed:21089071}.
FT                                /FTId=VAR_064827.
FT   VARIANT      44     44       V -> D (in LGSS; dbSNP:rs121434318).
FT                                {ECO:0000269|PubMed:19443465,
FT                                ECO:0000269|PubMed:20108422}.
FT                                /FTId=VAR_064828.
FT   CONFLICT      6      7       AT -> GL (in Ref. 1; AAP59414).
FT                                {ECO:0000305}.
FT   STRAND       13     24       {ECO:0000244|PDB:3SYX}.
FT   STRAND       26     29       {ECO:0000244|PDB:3SYX}.
FT   STRAND       31     37       {ECO:0000244|PDB:3SYX}.
FT   STRAND       40     51       {ECO:0000244|PDB:3SYX}.
FT   STRAND       54     64       {ECO:0000244|PDB:3SYX}.
FT   TURN         65     67       {ECO:0000244|PDB:3SYX}.
FT   STRAND       70     75       {ECO:0000244|PDB:3SYX}.
FT   STRAND       81     86       {ECO:0000244|PDB:3SYX}.
FT   STRAND       89     94       {ECO:0000244|PDB:3SYX}.
FT   STRAND       97    105       {ECO:0000244|PDB:3SYX}.
FT   HELIX       106    121       {ECO:0000244|PDB:3SYX}.
FT   HELIX       122    124       {ECO:0000244|PDB:3SYX}.
SQ   SEQUENCE   444 AA;  50477 MW;  6FFDECCE590DB311 CRC64;
     MSEETATSDN DNSYARVRAV VMTRDDSSGG WLPLGGSGLS SVTVFKVPHQ EENGCADFFI
     RGERLRDKMV VLECMLKKDL IYNKVTPTFH HWKIDDKKFG LTFQSPADAR AFDRGIRRAI
     EDISQGCPES KNEAEGADDL QANEEDSSSS LVKDHLFQQE TVVTSEPYRS SNIRPSPFED
     LNARRVYMQS QANQITFGQP GLDIQSRSME YVQRQISKEC GSLKSQNRVP LKSIRHVSFQ
     DEDEIVRINP RDILIRRYAD YRHPDMWKND LERDDADSSI QFSKPDSKKS DYLYSCGDET
     KLSSPKDSVV FKTQPSSLKI KKSKRRKEDG ERSRCVYCQE RFNHEENVRG KCQDAPDPIK
     RCIYQVSCML CAESMLYHCM SDSEGDFSDP CSCDTSDDKF CLRWLALVAL SFIVPCMCCY
     VPLRMCHRCG EACGCCGGKH KAAG
//
ID   T132E_HUMAN             Reviewed;        1074 AA.
AC   Q6IEE7; A0A0J9YW40; Q8WUF4; Q8WVA5;
DT   15-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   10-APR-2019, sequence version 2.
DT   13-NOV-2019, entry version 99.
DE   RecName: Full=Transmembrane protein 132E {ECO:0000305};
DE   Flags: Precursor;
GN   Name=TMEM132E {ECO:0000312|HGNC:HGNC:26991};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 340-1074.
RC   TISSUE=Adrenal cortex, and Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION, AND DISEASE.
RX   PubMed=14569139; DOI=10.1136/jmg.40.10.e116;
RA   Kehrer-Sawatzki H., Tinschert S., Jenne D.E.;
RT   "Heterogeneity of breakpoints in non-LCR-mediated large constitutional
RT   deletions of the 17q11.2 NF1 tumour suppressor region.";
RL   J. Med. Genet. 40:E116-E116(2003).
RN   [4]
RP   INVOLVEMENT IN DFNB99, VARIANT GLN-510, FUNCTION, AND VARIANT DFNB99
RP   GLN-510.
RX   PubMed=25331638; DOI=10.1002/humu.22712;
RA   Li J., Zhao X., Xin Q., Shan S., Jiang B., Jin Y., Yuan H., Dai P.,
RA   Xiao R., Zhang Q., Xiao J., Shao C., Gong Y., Liu Q.;
RT   "Whole-exome sequencing identifies a variant in TMEM132E causing
RT   autosomal-recessive nonsyndromic hearing loss DFNB99.";
RL   Hum. Mutat. 36:98-105(2015).
CC   -!- FUNCTION: Required for normal inner ear hair cell function and
CC       hearing. {ECO:0000269|PubMed:25331638}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Single-pass type I
CC       membrane protein {ECO:0000305}.
CC   -!- DISEASE: Note=TMEM132E is located in a region involved in a
CC       heterozygous deletion of approximately 4.7 Mb; this deletion,
CC       involving the NF1 gene and contiguous genes lying in its flanking
CC       regions, is observed in a patient with 17q11.2 microdeletion
CC       syndrome, a syndrome characterized by variable facial dysmorphism,
CC       mental retardation, developmental delay, and an excessive number
CC       of neurofibromas. {ECO:0000269|PubMed:14569139}.
CC   -!- DISEASE: Deafness, autosomal recessive, 99 (DFNB99) [MIM:618481]:
CC       A form of non-syndromic deafness characterized by prelingual,
CC       bilateral, severe-to-profound sensorineural hearing loss.
CC       Sensorineural deafness results from damage to the neural receptors
CC       of the inner ear, the nerve pathways to the brain, or the area of
CC       the brain that receives sound information.
CC       {ECO:0000269|PubMed:25331638}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TMEM132 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD80169.1; Type=Miscellaneous discrepancy; Note=Artifactual sequence.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AC005691; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC018318; AAH18318.1; -; mRNA.
DR   EMBL; BC020591; AAH20591.1; -; mRNA.
DR   EMBL; BN000149; CAD80169.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS11283.2; -.
DR   RefSeq; NP_001291367.1; NM_001304438.1.
DR   STRING; 9606.ENSP00000316532; -.
DR   iPTMnet; Q6IEE7; -.
DR   PhosphoSitePlus; Q6IEE7; -.
DR   BioMuta; TMEM132E; -.
DR   DMDM; 74709535; -.
DR   MassIVE; Q6IEE7; -.
DR   PaxDb; Q6IEE7; -.
DR   PeptideAtlas; Q6IEE7; -.
DR   PRIDE; Q6IEE7; -.
DR   ProteomicsDB; 66409; -.
DR   Ensembl; ENST00000631683; ENSP00000487800; ENSG00000181291.
DR   GeneID; 124842; -.
DR   KEGG; hsa:124842; -.
DR   UCSC; uc002hif.3; human.
DR   CTD; 124842; -.
DR   DisGeNET; 124842; -.
DR   GeneCards; TMEM132E; -.
DR   HGNC; HGNC:26991; TMEM132E.
DR   HPA; HPA070608; -.
DR   MIM; 616178; gene.
DR   MIM; 618481; phenotype.
DR   neXtProt; NX_Q6IEE7; -.
DR   OpenTargets; ENSG00000181291; -.
DR   Orphanet; 90636; Autosomal recessive non-syndromic sensorineural deafness type DFNB.
DR   PharmGKB; PA143485655; -.
DR   eggNOG; KOG4789; Eukaryota.
DR   eggNOG; ENOG410XQCD; LUCA.
DR   GeneTree; ENSGT00940000158479; -.
DR   HOGENOM; HOG000154481; -.
DR   InParanoid; Q6IEE7; -.
DR   KO; K17599; -.
DR   OMA; VECKSNN; -.
DR   OrthoDB; 598074at2759; -.
DR   PhylomeDB; Q6IEE7; -.
DR   TreeFam; TF314981; -.
DR   ChiTaRS; TMEM132E; human.
DR   GenomeRNAi; 124842; -.
DR   Pharos; Q6IEE7; -.
DR   PRO; PR:Q6IEE7; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000181291; Expressed in 127 organ(s), highest expression level in right hemisphere of cerebellum.
DR   ExpressionAtlas; Q6IEE7; baseline and differential.
DR   Genevisible; Q6IEE7; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR026307; TMEM132.
DR   InterPro; IPR031436; TMEM132_C.
DR   InterPro; IPR031437; TMEM132_M.
DR   InterPro; IPR031435; TMEM132_N.
DR   PANTHER; PTHR13388; PTHR13388; 1.
DR   Pfam; PF16070; TMEM132; 1.
DR   Pfam; PF15706; TMEM132D_C; 1.
DR   Pfam; PF15705; TMEM132D_N; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Deafness; Disease mutation; Glycoprotein; Membrane;
KW   Non-syndromic deafness; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26   1074       Transmembrane protein 132E.
FT                                /FTId=PRO_0000287103.
FT   TOPO_DOM     26    893       Extracellular. {ECO:0000255}.
FT   TRANSMEM    894    914       Helical. {ECO:0000255}.
FT   TOPO_DOM    915   1074       Cytoplasmic. {ECO:0000255}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     91     91       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    399    399       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT     510    510       R -> Q (in DFNB99; dbSNP:rs139895222).
FT                                {ECO:0000269|PubMed:25331638}.
FT                                /FTId=VAR_073717.
FT   CONFLICT    534    534       V -> F (in Ref. 2; AAH20591).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1074 AA;  116150 MW;  26257CBDD25FE880 CRC64;
     MAPGMSGRGG AALLCLSALL AHASGRSHPA SPSPPGPQAS PVLPVSYRLS HTRLAFFLRE
     ARPPSPAVAN SSLQRSEPFV VFQTKELPVL NVSLGPFSTS QVVARELLQP SSTLDIPERL
     TVNWKVRAFI VRSHVPASQP VVQVLFYVAG RDWDDFGVTE RLPCVRLHAF RDAREVKSSC
     RLSGGLATCL VRAELPLAWF GPPAPAAPPT ARRKSPDGLE PEATGESQQA ELYYTLHAPD
     ASGGCGGSRR GAGPGVGARA ESPTQHPLLR IGSISLFRPP PRRTLQEHRL DSNLMIRLPD
     RPLKPGEVLS ILLYLAPNSS SPSSPSVEHF TLRVKAKKGV TLLGTKSRSG QWHVTSELLT
     GAKHSTATVD VAWAQSTPLP PREGQGPLEI LQLDFEMENF TSQSVKRRIM WHIDYRGHGA
     LPDLERAVTE LTVIQRDVQA ILPLAMDTEI INTAILTGRT VAIPVKVIAI EVNGLVLDIS
     ALVECESDNE DIIKVSSSCD YVFVSGKESR GSMNARVTFR YDVLNAPLEM TVWVPKLPLH
     IELSDARLSQ VKGWRVPILP DRRSVRESED EDEEEEERRQ SASRGCTLQY QHATLQVFTQ
     FHTTSSEGTD QVVTMLGPDW LVEVTDLVSD FMRVGDPRVA HMVDSSTLAG LEPGTTPFKV
     VSPLTEAVLG ETLLTVTEEK VSITQLQAQV VASLALSLRP SPGSSHTILA TTAAQQTLSF
     LKQEALLSLW LSYSDGTTAP LSLYSPRDYG LLVSSLDEHV ATVTQDRAFP LVVAEAEGSG
     ELLRAELTIA ESCQKTKRKS VLATTPVGLR VHFGRDEEDP TYDYPGPSQP GPGGGEDEAR
     GAGPPGSALP APEAPGPGTA SPVVPPTEDF LPLPTGFLQV PRGLTDLEIG MYALLGVFCL
     AILVFLINCI VFVLRYRHKR IPPEGQTSMD HSHHWVFLGN GQPLRVQGEL SPPAGNPLET
     VPAFCHGDHH SSGSSQTSVQ SQVHGRGDGS SGGSARDQAE DPASSPTSKR KRVKFTTFTT
     LPSEELAYDS VPAGEEDEEE EEDLGWGCPD VAGPTRPTAP PDLHNYMRRI KEIA
//
ID   Q63946_9RODE            Unreviewed;        46 AA.
AC   Q63946;
DT   01-NOV-1996, integrated into UniProtKB/TrEMBL.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 36.
DE   SubName: Full=Neu protein {ECO:0000313|EMBL:AAB29944.1};
DE   Flags: Fragment;
GN   Name=neu {ECO:0000313|EMBL:AAB29944.1};
OS   Cricetinae (hamsters).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
OC   Muroidea; Cricetidae.
OX   NCBI_TaxID=10026 {ECO:0000313|EMBL:AAB29944.1};
RN   [1] {ECO:0000313|EMBL:AAB29944.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=7906199;
RA   Nakamura T., Ushijima T., Ishizaka Y., Nagao M., Nemoto T., Hara M.,
RA   Ishikawa T.;
RT   "neu proto-oncogene mutation is specific for the neurofibromas in a N-
RT   nitroso-N-ethylurea-induced hamster neurofibromatosis model but not
RT   for hamster melanomas and human Schwann cell tumors.";
RL   Cancer Res. 54:976-980(1994).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; S69086; AAB29944.1; -; Genomic_DNA.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
PE   4: Predicted;
KW   Membrane {ECO:0000256|SAM:Phobius};
KW   Transmembrane {ECO:0000256|SAM:Phobius};
KW   Transmembrane helix {ECO:0000256|SAM:Phobius}.
FT   TRANSMEM      6     26       Helical. {ECO:0000256|SAM:Phobius}.
FT   NON_TER      46     46       {ECO:0000313|EMBL:AAB29944.1}.
SQ   SEQUENCE   46 AA;  5293 MW;  5CCDE65B61A76071 CRC64;
     PATSIIATVE GILLFLVIGV VVGILIKRRR QKIRKYTMRR LLQETE
//
